Document:

EX-10.1

 Exhibit 10.1 

Execution Version 

INVESTMENT AGREEMENT 
 by
and among 
 NIKOLA CORPORATION, 

NIKOLA SUBSIDIARY CORPORATION 

and 
 THE PARTIES LISTED HEREIN

 Dated as of April 30, 2022 

 TABLE OF CONTENTS 

 
  

 

					
	 	  	PAGE	 
	
	ARTICLE 1	 
	DEFINITIONS	 
		
	 Section 1.01. Definitions
	  	 	1	 
	 Section 1.02. General Interpretive Principles
	  	 	9	 
	
	ARTICLE 2	 
	SALE AND PURCHASE OF THE NOTES	 
		
	 Section 2.01. Sale and Purchase of the Notes
	  	 	10	 
	 Section 2.02. The Closing
	  	 	10	 
	 Section 2.03. Termination
	  	 	12	 
	
	ARTICLE 3	 
	REPRESENTATIONS AND WARRANTIES	 
		
	 Section 3.01. Representations and Warranties of the Company and the
Guarantors
	  	 	13	 
	 Section 3.02. Representations and Warranties of Each Purchaser
	  	 	23	 
	
	ARTICLE 4	 
	ADDITIONAL AGREEMENTS	 
		
	 Section 4.01. Taking of Necessary Action
	  	 	26	 
	 Section 4.02. Securities Laws
	  	 	26	 
	 Section 4.03. Lost, Stolen, Destroyed or Mutilated Securities
	  	 	26	 
	 Section 4.04. Antitrust Approval
	  	 	27	 
	 Section 4.05. Conversion Price Matters
	  	 	27	 
	 Section 4.06. Nasdaq Approval
	  	 	27	 
	 Section 4.07. DTC Eligibility
	  	 	28	 
	 Section 4.08. Authorized and Reserved Company Common Stock
	  	 	28	 
	 Section 4.09. Hedging
	  	 	28	 
	 Section 4.10. Indemnification
	  	 	28	 
	 Section 4.11. Certain Tax Matters
	  	 	30	 
	
	ARTICLE 5	 
	REGISTRATION RIGHTS	 
		
	 Section 5.01. Registration Statement
	  	 	30	 
	 Section 5.02. Registration Limitations and Obligations
	  	 	31	 
	 Section 5.03. Registration Procedures
	  	 	33	 
	 Section 5.04. Expenses
	  	 	37	 
	 Section 5.05. Registration Indemnification
	  	 	37	 
	 Section 5.06. Facilitation of Sales Pursuant to Rule 144
	  	 	40	 

  
 i 

					
	ARTICLE 6	 
	MISCELLANEOUS	 
		
	 Section 6.01. Survival of Representations and Warranties
	  	 	40	 
	 Section 6.02. Notices
	  	 	40	 
	 Section 6.03. Entire Agreement; Third Party Beneficiaries; Amendment
	  	 	41	 
	 Section 6.04. Counterparts
	  	 	41	 
	 Section 6.05. Public Announcements
	  	 	42	 
	 Section 6.06. Expenses
	  	 	42	 
	 Section 6.07. Successors and Assigns
	  	 	42	 
	 Section 6.08. Governing Law; Jurisdiction; Waiver of Jury Trial
	  	 	43	 
	 Section 6.09. Severability
	  	 	44	 
	 Section 6.10. Specific Performance
	  	 	44	 
	 Section 6.11. Headings
	  	 	44	 
	 Section 6.12. Non-Recourse
	  	 	44	 
		
	 Schedules and Exhibits
	  			
		
	 Schedule 1: Purchasers
	  			
	 Schedule 2: Guarantors
	  			
	 Exhibit A: Form of Indenture
	  			
	 Exhibit B: Form of Joinder
	  			

  
 ii 

 INVESTMENT AGREEMENT 

This INVESTMENT AGREEMENT (this “Agreement”), dated as of April 30, 2022 by and among Nikola Corporation, a Delaware
corporation (together with any successor or assign pursuant to Section 6.07, the “Company”), Nikola Subsidiary Corporation, a Delaware corporation, and the several Purchasers listed on Schedule 1 hereto (together with their
successors and permitted assigns, each a “Purchaser” and, collectively, the “Purchasers”). Capitalized terms not otherwise defined where used shall have the meanings ascribed thereto in Article 1. 

WHEREAS, each Purchaser desires to purchase from the Company, and the Company desires to issue and sell to such Purchaser, severally and not
jointly, the respective principal amount of the Company’s 8.00% / 11.00% Convertible Senior PIK Toggle Notes due 2026 in the form attached to the Indenture (as defined below)(referred to herein as the “Note” or the
“Notes”) set forth opposite such Purchaser’s name in Schedule 1 hereto, to be issued in accordance with the terms and conditions of the indenture to be dated as of the Closing Date (as defined below), by and among
the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), in the form attached hereto as Exhibit A (the “Indenture”), on the terms and subject to the conditions set forth in
this Agreement; 
 WHEREAS, the payment of principal of, premium, if any, and interest on the Notes will be fully and unconditionally
guaranteed on a senior basis, jointly and severally, by (i) the guarantors listed in Schedule 2 hereto (the “Guarantors”) and (ii) any Company Subsidiary formed or acquired after the issuance of the Notes that
executes an additional guarantee in accordance with the terms of the Indenture, and their respective successors and assigns, pursuant to their guarantees (the “Note Guarantees”). All references herein to the Notes shall be
deemed to include the Guarantees; 
 WHEREAS, the Company and each Purchaser desire to enter into certain agreements set forth herein; and

 WHEREAS, prior to the execution hereof, the Board of Directors (as defined below) approved and authorized the execution and delivery of
this Agreement and the other Transaction Agreements (as defined below) and the consummation of the transactions contemplated hereby and thereby. 

NOW, THEREFORE, in consideration of the premises and the representations, warranties and agreements herein contained and intending to be
legally bound hereby, the parties hereby agree as follows: 
 ARTICLE 1 

DEFINITIONS 
 Section 1.01.
Definitions. As used in this Agreement, the following terms shall have the meanings set forth below: 
 “Action”
shall have the meaning set forth in Section 4.10(a). 

 “Affiliate” shall mean, with respect to any Person, any other Person which
directly or indirectly controls or is controlled by or is under common control with such Person. Notwithstanding the foregoing, with respect to each Purchaser (i) the Company and the Company’s Subsidiaries shall not be considered
Affiliates of such Purchaser or any of such Purchaser’s Affiliates and (ii) for purposes of the definitions of “Beneficially Own” and “Registrable Securities” and Sections 3.02(d), 3.02(f) and 4.04, no portfolio company
of a Purchaser or its Affiliates shall be deemed an Affiliate of such Purchaser and its other Affiliates so long as such portfolio company has not been directed, encouraged, instructed, assisted or advised by, or coordinated with, such Purchaser or
any of its Affiliates in carrying out any act prohibited by this Agreement. As used in this definition, “control” (including its correlative meanings, “controlled by” and “under common control with”) shall mean
possession, directly or indirectly, of power to direct or cause the direction of management or policies (whether through ownership of securities or partnership or other ownership interests, by contract or otherwise). 

“Agreement” shall have the meaning set forth in the preamble hereto. 

“Announcement Date” shall have the meaning set forth in Section 4.05. 

“Anti-Money Laundering Laws” shall have the meaning set forth in Section 3.01(n)(ii). 

“Associate” shall have the meaning set forth in Rule 12b-2 promulgated by the SEC
under the Exchange Act; provided that with respect to each Purchaser (i) the Company and the Company’s Subsidiaries will not be considered Associates of such Purchaser or any of its Affiliates and (ii) no portfolio company of
such Purchaser or its other Affiliates will be deemed Associates of such Purchaser or any of its other Affiliates. 

“Available” means, with respect to a Registration Statement, that such Registration Statement is effective and there is no
stop order with respect thereto and such Registration Statement does not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading such that such Registration Statement will be available for the resale of Registrable Securities. 

“Average VWAP” shall have the meaning set forth in Section 4.05. 

“Beneficially Own,” “Beneficially Owned,” “Beneficial Ownership” and “Beneficial
Owner” shall have the meaning set forth in Rule 13d-3 of the rules and regulations promulgated under the Exchange Act, except that for purposes of this Agreement the words “within sixty
days” in Rule 13d-3(d)(1)(i) shall not apply, to the effect that a person shall be deemed to be the Beneficial Owner of a security if that person has the right to acquire Beneficial Ownership of such
security at any time. Solely for purposes of determining the number of shares of Company Common Stock issuable upon conversion of the Notes Beneficially Owned by each Purchaser and its Affiliates, the Notes shall be treated as if upon conversion the
only settlement option under the Notes and the Indenture was for settlement in shares of Company Common Stock. For the avoidance of doubt, for purposes of this Agreement, each Purchaser (or any other person) shall at all times be deemed to have
Beneficial Ownership of shares of Company Common Stock issuable upon conversion of the Notes directly or indirectly held by them, irrespective of any non-conversion period specified in the Notes or this
Agreement or any restrictions on transfer or voting contained in this Agreement. 

  
 2 

 “Blackout Period” means in the event that the Company determines in good
faith that any registration or sale pursuant to any registration statement would reasonably be expected to materially adversely affect or materially interfere with any bona fide financing of the Company or any material transaction under
consideration by the Company or would require disclosure of information that has not been, and is not otherwise required to be, disclosed to the public, the premature disclosure of which would adversely affect the Company in any material respect, a
period of up to sixty (60) days; provided that a Blackout Period may not be called by the Company more than twice in any period of twelve (12) consecutive months. 

“Board of Directors” shall mean the board of directors of the Company. 

“Breach” shall have the meaning set forth in Section 3.01(r). 

“Business Day” shall mean any day, other than a Saturday, Sunday or a day on which banking institutions in the City of New
York, New York are authorized or obligated by law or executive order to remain closed. 
 “Capitalization Method” shall
have the meaning set forth in the Indenture. 
 “Capital Stock” means, for any entity, any and all shares, interests,
rights to purchase, warrants, options, participations or other equivalents of or interests in (however designated) stock issued by that entity. 

“Change in Control” shall mean the occurrence of any of the following events following the date hereof: 

 

	 	(i)	 a “person” or “group” within the meaning of Section 13(d) of the Exchange Act, other
than the Company, its Wholly Owned Subsidiaries and the employee benefit plans of the Company and its Wholly Owned Subsidiaries, files a Schedule TO or any schedule, form or report under the Exchange Act disclosing that such person or group has
become the direct or indirect “beneficial owner,” as defined in Rule 13d-3 under the Exchange Act, of the Common Stock representing more than 50% of the voting power of the Common Stock;

  

	 	(ii)	 the consummation of (A) any recapitalization, reclassification or change of the Common Stock (other than
changes resulting from a subdivision or combination) as a result of which the Common Stock would be converted into, or exchanged for, stock, other securities, other property or assets; (B) any share exchange, consolidation or merger of the
Company pursuant to which the Common Stock will be converted into cash, securities or other property or assets; or (C) any sale, lease or other transfer in one transaction or a series of transactions of all or substantially all of the
consolidated assets of the Company and its Subsidiaries, taken as a whole, to any Person other than one of the Company’s Wholly Owned Subsidiaries; provided, however, that a transaction described in clause (B) in which the holders
of all classes of the Company’s Common Equity immediately 

  
 3 

	 	
prior to such transaction own, directly or indirectly, more than 50% of all classes of Common Equity of the continuing or surviving Person or transferee or the parent thereof immediately after
such transaction in substantially the same proportions (relative to each other) as such ownership immediately prior to such transaction shall not be a Change in Control pursuant to this clause (b); 

 

	 	(iii)	 the stockholders of the Company approve any plan or proposal for the liquidation or dissolution of the Company.

 “Closing” shall have the meaning set forth in Section 2.02. 

“Closing Date” shall have the meaning set forth in Section 2.02. 

“Common Equity” of any Person means Capital Stock of such Person that is generally entitled (a) to vote in the election
of directors of such Person or (b) if such Person is not a corporation, to vote or otherwise participate in the selection of the governing body, partners, managers or others that will control the management or policies of such Person. 

“Company” shall have the meaning set forth in the preamble hereto. 

“Company Common Stock” shall mean the common stock, $0.0001 par value per share, of the Company. 

“Company Owned Intellectual Property Rights” shall have the meaning set forth in Section 3.01(o). 

“Company Reports” shall have the meaning set forth in Section 3.01(g)(i). 

“Company Subsidiary” shall mean a Subsidiary of the Company. 

“Conversion Price” shall have the meaning set forth in the Indenture. 

“Conversion Rate” shall have the meaning set forth in the Indenture. 

“Daily VWAP” shall have the meaning set forth in the Indenture. 

“Data Security Obligations” shall have the meaning set forth in Section 3.01(q). 

“Disclosure Document” shall have the meaning set forth in Section 6.05. 

“DTC” shall have the meaning set forth in Section 2.01(b). 

“End Date” shall have the meaning set forth in Section 2.03(a). 

“Enforceability Exceptions” shall have the meaning set forth in Section 3.01(c). 

“Environmental Laws” shall have the meaning set forth in Section 3.01(s). 

“Exchange Act” shall mean the U.S. Securities Exchange Act of 1934, as amended. 

  
 4 

 “GAAP” shall mean U.S. generally accepted accounting principles. 

“Government Official” shall have the meaning set forth in Section 3.01(n)(i). 

“Governmental Entity” shall mean any court, administrative agency or commission or other governmental authority or
instrumentality, whether federal, state, local or foreign, and any applicable industry self-regulatory organization. 

“Guarantor” shall have the meaning set forth in the recitals. 

“HSR Act” shall mean the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations
promulgated thereunder. 
 “Indemnification Notice” shall have the meaning set forth in Section 4.10(b). 

“Indemnified Persons” shall have the meaning set forth in Section 5.05(a). 

“Indemnitee” shall have the meaning set forth in Section 4.10(a). 

“Indenture” shall have the meaning set forth in the recitals. 

“Intellectual Property Rights” shall have the meaning set forth in Section 3.01(o). 

“IT Systems and Data” shall have the meaning set forth in Section 3.01(r). 

“Joinder” shall mean, with respect to any Person permitted to sign such document in accordance with the terms hereof, a
joinder executed and delivered by such Person, providing such Person to have all the rights and obligations of a Purchaser under this Agreement, in form and substance substantially as attached hereto as Exhibit B or such other form as may be
agreed to by the Company and a Purchaser. 
 “Losses” shall have the meaning set forth in Section 5.05(a). 

“Material Adverse Effect” shall mean: any events, changes or developments that, individually or in the aggregate: 

(i) have a material adverse effect on the business, financial condition or results of operations of the Company and its Subsidiaries, taken as
a whole, other than any event, change or development resulting from or arising out of the following: 
  

	 	(a)	 events, changes or developments generally affecting the economy, the financial or securities markets, or
political, legislative or regulatory conditions, in each case in the United States or elsewhere in the world; 

  

	 	(b)	 events, changes or developments in the industries in which the Company or any Company Subsidiary conducts its
business; 

  

	 	(c)	 any adoption, implementation, promulgation, repeal, modification, reinterpretation or proposal of any rule,
regulation, ordinance, order, protocol or any other law of or by any national, regional, state or local Governmental Entity, or market administrator; 

  
 5 

	 	(d)	 any changes in GAAP or accounting standards or interpretations thereof; 

 

	 	(e)	 epidemics, pandemics, earthquakes, any weather-related or other force majeure event or natural disasters or
outbreak or escalation of hostilities or acts of war or terrorism or cyberattacks; 

  

	 	(f)	 the announcement or the existence of, compliance with or performance under, this Agreement or the transactions
contemplated hereby; 

  

	 	(g)	 any taking of any action at the request of any Purchaser; 

 

	 	(h)	 any failure by the Company to meet any financial projections or forecasts or estimates of revenues, earnings or
other financial metrics for any period (provided that the exception in this clause (h) shall not prevent or otherwise affect a determination that any event, change, effect or development underlying such failure has resulted in a Material
Adverse Effect so long as it is not otherwise excluded by this definition); or 

  

	 	(i)	 any changes in the share price or trading volume of the Company Common Stock or in the Company’s credit
rating (provided that the exception in this clause (i) shall not prevent or otherwise affect a determination that any event, change, effect or development underlying such change has resulted in a Material Adverse Effect so long as it is
not otherwise excluded by this definition); 

 except, in each case with respect to subclauses (a) through (e),
to the extent that such event, change or development disproportionately affects the Company and its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which the Company and its Subsidiaries operate;
or 
 (ii) materially and adversely affect or delay the Company’s or the Guarantor’s power or ability to consummate the
Transactions or perform their respective obligations under the Transaction Agreements. 
 “Nasdaq” shall mean The Nasdaq
Stock Market. 
 “Note” or “Notes” shall have the meaning set forth in the recitals. 

“Note Guarantee” shall have the meaning set forth in the recitals. 

“Open Source Software” shall have the meaning set forth in Section 3.01(p). 

“Permitted Counterparty” means a nationally recognized financial institution that enters into one or more swap, hedging or
other derivative arrangements with one or more Purchasers in connection with a bona fide financing of the purchase of the Notes. 

  
 6 

 “Person” or “person” shall mean an individual,
corporation, limited liability or unlimited liability company, association, partnership, trust, estate, joint venture, business trust or unincorporated organization, or a government or any agency or political subdivision thereof, or other entity of
any kind or nature. 
 “Personal Data” shall have the meaning set forth in Section 3.01(q). 

“PIK Interest” shall have the meaning set forth in the Indenture. 

“PIK Shares” shall have the meaning set forth in Section 5.01(a). 

“Purchase Price” shall have the meaning set forth in Section 2.01. 

“Purchaser” shall have the meaning set forth in the preamble hereto. 

“Purchaser Affiliates” means, collectively and individually, the Affiliates and Associates of each Purchaser. 

“Registrable Securities” shall mean the Subject Securities; provided that any Subject Securities will cease to be
Registrable Securities when 
  

	 	(w)	 such Subject Securities have been sold or otherwise disposed of pursuant to an effective Registration Statement
or in compliance with Rule 144 and any restrictive legend has been removed in connection therewith; 

  

	 	(x)	 such Subject Securities cease to be outstanding; or 

 

	 	(y)	 if the Company consolidates or merges with or into any Person in a transaction that constitutes a Change in
Control and the Subject Securities are converted into or exchanged for securities of a different issuer and/or cash and such other securities are not listed on Nasdaq, the New York Stock Exchange or any other nationally recognized securities
exchange; 

 provided that any security that has ceased to be Registrable Securities in accordance with the foregoing definition
shall not thereafter become Registrable Securities and any security that is issued or distributed in respect of securities that have ceased to be Registrable Securities are not Registrable Securities. 

“Registration Date” shall have the meaning set forth in Section 5.01(a). 

“Registration Expenses” shall mean all expenses incurred by the Company in complying with Article 5, including all
registration, listing and filing fees, printing expenses, fees and disbursements of counsel and independent public accountants for the Company and reasonable and documented fees and disbursements of counsel to the Selling Holders (not to exceed
$50,000), fees and expenses incurred by the Company in connection with complying with state securities or “blue sky” laws, fees of the Financial Industry Regulatory Authority, Inc., transfer taxes, and fees of transfer agents and
registrars, but excluding any underwriting fees, discounts and selling commissions, agency fees, brokers’ commissions and transfer taxes, in each case to the extent applicable to the Registrable Securities of the Selling Holders. 

  
 7 

 “Registration Statement” shall mean any registration statement of the
Company filed or to be filed with the SEC under the rules and regulations promulgated under the Securities Act, including the related prospectus, amendments and supplements to such registration statement, and including
pre- and post-effective amendments, and all exhibits and all material incorporated by reference in such registration statement. 

“Registration Termination Date” shall have the meaning set forth in Section 5.01(b). 

“Rule 144” shall mean Rule 144 promulgated by the SEC pursuant to the Securities Act, as such rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same effect as such rule. 
 “Rule
144A” shall mean Rule 144A promulgated by the SEC pursuant to the Securities Act, as such rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same effect as such
rule. 
 “Rule 405” shall mean Rule 405 promulgated by the SEC pursuant to the Securities Act, as such rule may be amended
from time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same effect as such rule. 

“Sanctions” shall have the meaning set forth in Section 3.01(n)(iii)(A). 

“SEC” shall mean the U.S. Securities and Exchange Commission. 

“Securities Act” shall mean the U.S. Securities Act of 1933, as amended. 

“Selling Holders” shall have the meaning set forth in Section 5.03(a)(i). 

“Specified Persons” shall have the meaning set forth in Section 6.12. 

“Subject Securities” shall mean: 
  

	 	(i)	 the shares of Company Common Stock issuable or issued upon conversion of the Notes; and 

 

	 	(ii)	 any securities issued as or pursuant to (or issuable upon the conversion, exercise or exchange of any warrant,
right or other security that is issued as or pursuant to) a dividend, stock split, combination or any reclassification, recapitalization, merger, consolidation, exchange or any other distribution or reorganization with respect to, or in exchange
for, or in replacement of, the securities referenced in clause (i) (without giving effect to any election by the Company regarding settlement options upon conversion) above or this clause (ii). 

“Subsidiary” shall mean, with respect to any Person, any other Person of which 50% or more of the shares of the voting
securities or other voting interests are owned or controlled, or the ability to select or elect 50% or more of the directors or similar managers is held, directly or indirectly, by such first Person or one or more of its Subsidiaries, or by such
first Person, or by such first Person and one or more of its Subsidiaries. 

  
 8 

 “Take-Down Notice” shall have the meaning set forth in
Section 5.02(b). 
 “Tax” or “Taxes” shall mean all federal, state, local, and foreign income,
excise, gross receipts, gross income, ad valorem, profits, gains, property, capital, sales, transfer, use, payroll, employment, severance, withholding, duties, intangibles, franchise, backup withholding, value-added, and other taxes imposed by a
Governmental Entity, together with all interest, penalties and additions to tax imposed with respect thereto. 
 “Tax
Return” shall mean a report, return or other document (including any amendments thereto) required to be supplied to a Governmental Entity with respect to Taxes. 

“Trading Day” shall have the meaning assigned thereto in the Indenture. 

“Transaction Agreements” shall have the meaning set forth in Section 3.01(c). 

“Transactions” shall have the meaning set forth in Section 3.01(c). 

“Trustee” shall have the meaning set forth in the recitals. 

“Tumim Agreements” shall have the meaning set forth in Section 3.01(b). 

“Underwritten Offering” shall mean a sale of Registrable Securities to an underwriter or underwriters for reoffering to the
public, including in a block trade offered and sold through an underwriter or underwriters. 
 “VWAP Period” shall have the
meaning set forth in Section 4.05. 
 “Wholly Owned Subsidiary” means, with respect to any Person, any Subsidiary of
such Person, except that, solely for purposes of this definition, the reference to “more than 50%” in the definition of “Subsidiary” shall be deemed replaced by a reference to “100%.” 

“WKSI” means a “well known seasoned issuer,” as defined under Rule 405. 

Section 1.02. General Interpretive Principles. Whenever used in this Agreement, except as otherwise expressly provided or unless the context
otherwise requires, any noun or pronoun shall be deemed to include the plural as well as the singular and to cover all genders. The name assigned to this Agreement and the section captions used herein are for convenience of reference only and shall
not be construed to affect the meaning, construction or effect hereof. Whenever the words “include,” “includes,” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without
limitation.” Unless otherwise specified, the terms “hereto,” “hereof,” “herein” and similar terms refer to this Agreement as a whole (including the exhibits, schedules and disclosure statements hereto), references
to “the date hereof” refer to the date of this Agreement and references herein to Articles or Sections refer to Articles or Sections of this Agreement. For the avoidance of doubt, notwithstanding anything in this Agreement to the

  
 9 

 
contrary, none of the Notes will have any right to vote or any right to receive any dividends or other distributions that are made or paid to the holders of the shares of Company Common Stock,
except as otherwise provided in the Indenture. References to any law or statute shall be deemed to refer to such law or statute as amended from time to time and, if applicable, to any rules or regulations promulgated thereunder. References to any
agreement or contract are to that agreement or contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof, except as otherwise provided herein or in the Indenture. 

ARTICLE 2 
 SALE
AND PURCHASE OF THE NOTES 
 Section 2.01. Sale and Purchase of the
Notes. 
  

	(a)	 Subject to the terms and conditions of this Agreement, the Company shall issue and sell to each Purchaser,
severally and not jointly, and such Purchaser shall purchase and acquire from the Company, the applicable principal amount of Notes at the Closing listed opposite such Purchaser’s name on Schedule 1 hereto for a purchase price equal to
the principal amount of such Notes (such price, the “Purchase Price”). 

  

	(b)	 Payment for the Notes shall be made to the Company in Federal or other funds immediately available against
delivery of such Notes for the respective accounts of the several Purchasers on the Closing Date. The Notes shall be in definitive form or global form, as specified by each Purchaser, and registered in such names and in such denominations as each
such Purchaser shall request in writing not later than one full business day prior to the Closing Date, as the case may be. The Notes shall be delivered for the respective accounts of each several Purchaser, with any transfer taxes payable in
connection with the transfer of the Notes to the Purchasers duly paid by the Company, against payment of the Purchase Price therefor. The Company shall cause such Notes to be available through the facilities of the Depositary Trust Company
(“DTC”) at the Closing. 

 Section 2.02. The Closing. 

 

	(a)	 Subject to the satisfaction or waiver of the conditions for the Closing set forth in this Section 2.02,
the Closing (the “Closing”) of the purchase and sale of the Notes hereunder shall take place at electronically at 11:00 a.m. Eastern time on June 3, 2022, or at such other place, time or date as may be mutually agreed upon in
writing by the Company and the Purchasers (the date on which the Closing actually occurs, the “Closing Date”). 

  

	(b)	 To effect the purchase and sale of Notes, upon the terms and subject to the conditions set forth in this
Agreement, at the Closing: 

  

	(i)	 the Company and the Trustee shall deliver the applicable portion of the Notes, registered in the name of each
Purchaser or through the facilities of The Depository Trust Company as elected by the Purchasers, against payment in full by or on behalf of such Purchaser of the applicable Purchase Price for the applicable portion of the Notes;

  
 10 

	(ii)	 each Purchaser shall cause a wire transfer to be made in same day funds to an account of the Company designated
in writing by the Company to the Purchasers in an amount equal to the Purchase Price for the applicable Notes; and 

  

	(iii)	 each Purchaser shall have caused to be delivered to the Company a duly completed and executed IRS Form W-8 or W-9, as applicable. 

  

	(c)	 The obligations of the Company and each Purchaser to consummate the Closing are subject to the satisfaction or
waiver of the following conditions: 

  

	(i)	 the purchase and sale of the Notes shall not be prohibited by law or enjoined by any governmental authority of
competent jurisdiction; and 

  

	(ii)	 the Company and the Purchasers shall have agreed upon the final form of the Indenture, including the table
contained in Section 14.03 thereof.. 

  

	(d)	 The obligations of each Purchaser to consummate the Closing are subject to the satisfaction or waiver of the
following conditions: 

  

	(i)	 (A) the representations and warranties of the Company set forth in Section 3.01(a), 3.01(c) and
(e) shall be true and correct in all material respects on and as of the Closing Date; (B) the representations and warranties of the Company set forth in (x) Section 3.01(b), (y) the last sentence of Section 3.01(g)(i) and
(z) Section 3.01(h) shall be true and correct on and as of the Closing Date and (C) the representations and warranties of the Company set forth in Sections 3.01, other than as described in the foregoing clauses (A) and (B) shall
be true and correct on and as of the Closing Date (without giving effect to materiality, Material Adverse Effect, or similar phrases in the representations and warranties), except where the failure of such representations and warranties referenced
in this clause (C) to be so true and correct, individually or in the aggregate, has not had and would not reasonably be expected to have a Material Adverse Effect; 

 

	(ii)	 the Company shall have performed and complied in all material respects with all agreements and obligations
required by this Agreement to be performed or complied with by it on or prior to the Closing; 

  

	(iii)	 each Purchaser shall have received a certificate, dated the Closing Date, duly executed by an executive officer
of the Company on behalf of the Company and the Guarantors, certifying that the conditions specified in Sections 2.02(d)(i) and 2.02(d)(ii) have been satisfied; 

 

	(iv)	 the Company and the Trustee shall have executed the applicable Notes and delivered a copy to each Purchaser;

  

	(v)	 the Company, the Guarantors and the Trustee shall have executed the Indenture, and copies of the Indenture
shall have been delivered to each Purchaser; and 

  

	(vi)	 the Notes shall be eligible for delivery through DTC. 

 

	(e)	 The obligations of the Company to sell the Notes to each Purchaser are subject to the satisfaction or waiver of
the following conditions as of the Closing: 

  
 11 

	(i)	 the representations and warranties of such Purchaser set forth in Section 3.02 shall be true and correct
in all material respects on and as of the Closing Date; 

  

	(ii)	 such Purchaser shall have performed and complied in all material respects with all agreements and obligations
required by this Agreement to be performed or complied with by it on or prior to the Closing Date; and 

  

	(iii)	 the Company shall have received a certificate, dated the Closing Date, duly executed by an authorized person of
such Purchaser, certifying that the conditions specified in Sections 2.02(e)(i) and 2.02(e)(ii) have been satisfied. 

 Section 2.03.
Termination. 
  

	(a)	 This Agreement may be terminated before the Closing: 

 

	(i)	 by mutual written agreement of the Company and each Purchaser (solely with respect to itself);

  

	(ii)	 by either the Company or a Purchaser (solely with respect to itself), if: 

 

	(A)	 the Closing has not been consummated on or before the 25th Business Day following the date of this Agreement
(the “End Date”); provided that the right to terminate this Agreement pursuant to this Section 2.03(a)(ii) shall not be available to any party whose breach of any provision of this Agreement results in the failure of the
Closing to be consummated by such time; or 

  

	(B)	 the purchase and sale of the Notes shall have been (1) prohibited by law or (2) enjoined by any
governmental authority of competent jurisdiction, and such injunction shall have become final and nonappealable. 

  

	(iii)	 by a Purchaser (solely with respect to itself), if a breach of any representation or warranty or failure to
perform any covenant or agreement on the part of the Company set forth in this Agreement shall have occurred that would cause the condition set forth in Section 2.02(d)(i) and Section 2.02(d)(ii) not to be satisfied, and such conditions
are incapable of being satisfied by the End Date; or 

  

	(iv)	 by the Company, if a breach of any representation or warranty or failure to perform any covenant or agreement
on the part of any Purchaser set forth in this Agreement shall have occurred that would cause the conditions set forth in Section 2.02(e)(i) and Section 2.02(e)(ii) not to be satisfied, and such conditions are incapable of being satisfied
by the End Date. 

  

	(b)	 If this Agreement is terminated pursuant to Section 2.03(a), this Agreement shall become void and of no
effect without liability of any party (or any stockholder, director, officer, employee, agent, consultant or representative of such party) to the other party with respect to whom this Agreement shall have terminated; provided that, if such
termination shall result from the intentional (i) failure of a party to fulfill a condition to the performance of the obligations of an other party or (ii) failure of a party to perform a covenant hereof, such party shall be fully liable
for any and all liabilities and damages incurred or suffered by an other party as a result of such failure. The provisions of this Section 2.03(b) and Sections 6.06, 6.08, 6.10 and 6.12 shall survive any termination hereof pursuant to
Section 2.03. 

  
 12 

	(c)	 Following the Closing, this Agreement may only be terminated by the mutual written agreement by the Company and
each Purchaser. 

 ARTICLE 3 

REPRESENTATIONS AND WARRANTIES 

Section 3.01. Representations and Warranties of the Company and the Guarantors. Except as disclosed in the Company Reports filed with or furnished
to the SEC and publicly available prior to the date hereof (excluding in each case any disclosures set forth in the risk factors or “forward-looking statements” sections of such reports, and any other disclosures included therein to the
extent they are predictive or forward-looking in nature), the Company and each Guarantor, jointly and severally, represents and warrants to the Purchasers, as of the date hereof and as of the Closing Date, as follows: 

(a) Existence and Power. 
  

	(i)	 The Company has been duly incorporated, is validly existing as a corporation in good standing under the laws of
the jurisdiction of its incorporation, has the corporate power and authority to own or lease its property and to conduct its business as it is being conducted on the date of this Agreement, and is duly qualified to transact business and is in good
standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not, singly or in the
aggregate, reasonably be expected to have a Material Adverse Effect. 

  

	(ii)	 Each Company Subsidiary has been duly incorporated, organized or formed, is validly existing as a corporation
or other business entity in good standing under the laws of the jurisdiction of its incorporation, organization or formation (to the extent that the concept of good standing is applicable in such jurisdiction), has the corporate or other business
entity power and authority to own or lease its property and to conduct its business as it is being conducted on the date of this Agreement, and is duly qualified to transact business and is in good standing (to the extent that the concept of good
standing is applicable in such jurisdiction) in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good
standing (to the extent that the concept of good standing is applicable in such jurisdiction) would not, singly or in the aggregate, reasonably be expected to have a Material Adverse Effect; all of the issued shares of capital stock or other equity
interests of each Company Subsidiary have been duly and validly authorized and issued, are fully paid and non-assessable and, except for directors’ qualifying shares, are owned directly or indirectly by
the Company, free and clear of all liens, encumbrances, equities or claims. 

  

	(b)	 Capitalization. The authorized share capital of the Company consists of 600,000,000 shares of Company
Common Stock and 150,000,000 shares of preferred stock, $0.0001 par value per share. As of December 31, 2021, there were (i) 413,340,550 shares of Company Common Stock issued and outstanding and no shares of preferred stock of the Company
issued and outstanding, (ii) options to purchase an aggregate of 28,996,160 shares of Company Common Stock outstanding, (iii) 25,496,384 shares of Company Common Stock underlying the Company’s outstanding restricted stock unit awards
(assuming maximum vesting of such awards) and (iv) 

  
 13 

	 	
warrants to purchase 760,915 shares of Company Common Stock issued and outstanding. Since December 31, 2021, (A) the Company has only issued options and restricted stock unit awards or other
rights to acquire shares of Company Common Stock in the ordinary course of business consistent with past practice and (B) the only shares of capital stock issued by the Company were pursuant to (x) the Company’s employee stock
purchase plan, (y) exercise or vesting of outstanding warrants, outstanding options, restricted stock unit awards and other compensatory rights to purchase shares of Company Common Stock granted to employees, directors or other service
providers, or (z) the Company’s purchase agreements with Tumim Stone Capital LLC, which agreements are described in the Company Reports (the “Tumim Agreements”). All outstanding shares of Company Common Stock are duly
authorized, validly issued, fully paid and nonassessable, and are not subject to and were not issued in violation of any preemptive or similar right, purchase option, call or right of first refusal or similar right. Except as disclosed in the
Company Reports filed with or furnished to the SEC and publicly available since March 1, 2021 and as provided in this Agreement and the Notes, there are no existing options, warrants, calls, preemptive (or similar) rights, subscriptions or
other rights, agreements or commitments obligating the Company to issue, transfer or sell, or cause to be issued, transferred or sold, any capital stock of the Company or any securities convertible into or exchangeable for such capital stock and
there are no current outstanding contractual obligations of the Company to repurchase, redeem or otherwise acquire any of its shares of capital stock, except with respect to the acquisition of shares of Company Common Stock by the Company to satisfy
the payment of the applicable exercise price or withholding taxes for equity awards. Since March 1, 2021, the Company has not declared or paid any dividends. 

 

	(c)	 Authorization. The execution, delivery and performance of this Agreement, the Indenture and the Notes
(collectively, the “Transaction Agreements”) and the consummation of the transactions contemplated herein and therein (collectively, the “Transactions”) have been duly authorized by the Board of Directors and all
other necessary corporate action on the part of the Company and the Guarantors. Assuming this Agreement constitutes the valid and binding obligation of each Purchaser, this Agreement is a valid and binding obligation of the Company and the
Guarantors, enforceable against them in accordance with its terms, subject to the limitation of such enforcement by (A) the effect of bankruptcy, insolvency, reorganization, receivership, conservatorship, arrangement, moratorium, fraudulent
transfer, preference or other laws affecting or relating to creditors’ rights generally or (B) the rules governing the availability of specific performance, injunctive relief or other equitable remedies and general principles of equity,
regardless of whether considered in a proceeding in equity or at law (the “Enforceability Exceptions”). On the Closing Date, each of the Indenture and the Note Guarantees will be duly executed and delivered by the Company and the
Guarantors, as the case may be, and, assuming due authorization, execution and delivery by the other parties thereto, will be a valid and binding obligation of the Company and the Guarantors, as the case may be, enforceable against them in
accordance with its terms, subject to the Enforceability Exceptions. 

  

	(d)	 General Solicitation; No Integration. Neither the Company nor any other Person or entity authorized by
the Company to act on its behalf has engaged in a general solicitation or general advertising (within the meaning of Regulation D of the Securities Act) of investors with respect to offers or sales of the Notes. The Company has not, directly or
indirectly, sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of, any security (as defined in the Securities Act) which, to its knowledge, is or will be integrated with the Notes sold pursuant to this Agreement.

  
 14 

	(e)	 Valid Issuance. The Notes have been duly authorized by all necessary corporate action of the Company.
When issued and sold against receipt of the consideration therefor, the Notes will be valid and legally binding obligations of the Company, enforceable in accordance with their terms against them, subject to the limitation of such enforcement by the
Enforceability Exceptions. The Company has available and has reserved for issuance the maximum number of shares (including make-whole shares) of Company Common Stock initially issuable upon conversion of the Notes if such conversion were to occur
immediately following Closing (assuming fully physical share settlement). The Company Common Stock to be issued upon conversion of the Notes in accordance with the terms of the Notes has been duly authorized and reserved for issuance, and when
issued upon conversion of the Notes, all such Company Common Stock will be validly issued, fully paid and nonassessable and free of pre-emptive or similar rights. 

 

	(f)	 Non-Contravention/No Consents. The execution, delivery and
performance of the Transaction Agreements, the issuance of the shares of Company Common Stock upon conversion of the Notes in accordance with their terms and the consummation by the Company and each of the Guarantors of the Transactions, does not
conflict with, violate or result in a breach of any provision of, or constitute a default under, or result in the termination of or accelerate the performance required by, or result in a right of termination or acceleration under, (i) the
certificate of incorporation or bylaws of the Company, (ii) any mortgage, note, indenture, deed of trust, lease, license, loan agreement or other agreement binding upon the Company or any Company Subsidiary or (iii) any permit, license,
judgment, order, decree, ruling, injunction, statute, law, ordinance, rule or regulation applicable to the Company or any Company Subsidiary other than in the cases of clauses (ii) and (iii) as would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect. Assuming the accuracy of the representations of each Purchaser set forth herein, other than (A) any required filings or approvals under the HSR Act or any foreign antitrust or
competition laws, requirements or regulations in connection with the issuance of shares of Company Common Stock upon the conversion of the Notes, (B) pursuant to any requirements or regulations in connection with the issuance of Company Common
Stock upon the conversion of the Notes, including the filing of a listing notice with Nasdaq or filings under state securities or “blue sky” laws, (C) any required filings pursuant to the Exchange Act or the rules of the SEC, Nasdaq
or state regulators, or (D) as have been obtained prior to the date of this Agreement, no consent, approval, order or authorization of, or registration, declaration or filing with, any Governmental Entity is required on the part of the Company
or any Company Subsidiary in connection with the execution, delivery and performance by the Company and the Guarantors of this Agreement and the consummation by the Company and the Guarantors of the Transactions (in each case other than the
transactions contemplated by Article 5), except for any consent, approval, order, authorization, registration, declaration, filing, exemption or review the failure of which to be obtained or made, individually or in the aggregate, would not
reasonably be expected to have a Material Adverse Effect. 

  

	(g)	 Reports; Financial Statements. 

  
 15 

	(i)	 The Company has filed with or furnished to the SEC, as applicable, (A) its annual report on Form 10-K for its fiscal year ended December 31, 2021, (B) its quarterly reports on Form 10-Q for its fiscal quarters ended March 31, June 31 and September 30,
2021, (C) its definitive proxy statement relating to the annual meeting of the stockholders of the Company held in 2021, and (D) all other forms, reports, schedules and other statements required to be filed or furnished by it with the SEC under
the Exchange Act or the Securities Act since March 1, 2021 (collectively, the “Company Reports”). As of its respective date, and, if amended, as of the date of the last such amendment, each Company Report complied in all
material respects as to form with the applicable requirements of the Securities Act and the Exchange Act, and any rules and regulations promulgated thereunder applicable to such Company Report. As of its respective date, and, if amended, as of the
date of the last such amendment, no Company Report contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements made therein, in the light of the
circumstances in which they were made, not misleading. 

  

	(ii)	 Each of the consolidated balance sheets, and the related consolidated statements of operations,
stockholders’ equity and cash flows, included in the Company Reports filed with the SEC under the Exchange Act (A) have been prepared from, and are in accordance with, the books and records of the Company and its Subsidiaries,
(B) fairly present in all material respects the consolidated financial position of the Company and its consolidated Subsidiaries as of the dates shown and the results of the consolidated operations, changes in stockholders’ equity and cash
flows of the Company and its consolidated Subsidiaries for the respective fiscal periods or as of the respective dates therein set forth, subject, in the case of any unaudited financial statements, to normal recurring
year-end adjustments, (C) have been prepared in accordance with GAAP consistently applied during the periods involved, except as otherwise set forth therein or in the notes thereto and, in the case of
unaudited financial statements, except for the absence of footnote disclosure, and (D) otherwise comply in all material respects with the requirements of the SEC. 

 

	(iii)	 Except as disclosed in Company Reports, the Company and its Subsidiaries have established and maintained a
system of internal control over financial reporting (as defined in Rule 13a-15 under the Exchange Act) sufficient to provide reasonable assurance regarding the reliability of the Company’s financial
reporting and the preparation of Company financial statements for external purposes in accordance with GAAP. 

  

	(iv)	 Except as disclosed in Company Reports and other than the transactions contemplated by this Agreement, there
has been no transaction, or series of related transactions, agreements, arrangements or understandings, nor is there any proposed transaction, or series of related transactions, agreements, arrangements or understandings, that would be required to
be disclosed under Item 404 of Regulation S-K promulgated by the SEC under the Securities Act that have not been disclosed in the Company Reports. 

 

	(h)	 Absence of Certain Changes. Since December 31, 2021, (i) the Company and its Subsidiaries have
conducted their respective businesses in all material respects in the ordinary course of business; and (ii) no events, changes or developments have occurred that, individually or in the aggregate, have had or would reasonably be expected to
have a Material Adverse Effect. 

  
 16 

	(i)	 No Undisclosed Liabilities, etc. As of the date hereof, there are no liabilities of the Company or any
Company Subsidiary that would be required by GAAP to be reflected on the face of the balance sheet, except (i) liabilities reflected or reserved against in the financial statements or disclosed in the notes thereto contained in the Company
Reports, (ii) liabilities incurred since December 31, 2021 in the ordinary course of business and (iii) liabilities that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

  

	(j)	 Compliance with Applicable Law. Each of the Company and its Subsidiaries has complied in all respects
with, and is not in default or violation in any respect of, any law, statute, order, rule, regulation, policy or guideline of any federal, state or local or international Governmental Entity having jurisdiction or otherwise applicable to the Company
and its Subsidiaries, other than as would not, individually or in the aggregate, have or reasonably be expected to have a Material Adverse Effect. 

  

	(k)	 Legal Proceedings. There are no legal or governmental proceedings pending or, to the Company’s
knowledge, threatened to which the Company or any Company Subsidiary is a party or to which any of the properties of the Company or any Company Subsidiary is subject that would, singly or in the aggregate, reasonably be expected to have a Material
Adverse Effect. 

  

	(l)	 Demand Rights. There are no contracts, agreements or understandings between the Company and any person
granting such person the right to require the Company to file a registration statement under the Securities Act with respect to any securities of the Company that are not already registered as of the date hereof, other than this Agreement and the
Tumim Agreements. 

  

	(m)	 Real and Personal Property. The Company and its Subsidiaries have good and marketable title in fee
simple to all items of real property described in the Company Reports as being owned by them, good and valid title to all personal property described in the Company Reports as being owned by them that are material to the businesses of the Company or
such Subsidiary, in each case free and clear of all liens, encumbrances and claims, except those matters that (i) do not materially interfere with the use made and proposed to be made of such property by the Company and any of its Subsidiaries
or (ii) would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. Any real or personal property described in the Company Reports as being leased by the Company and any of its Subsidiaries is held by
them under valid, existing and enforceable leases, except those that (A) do not materially interfere with the use made or proposed to be made of such property by the Company or any of its Subsidiaries or (B) would not be reasonably
expected, individually or in the aggregate, to have a Material Adverse Effect. Each of the properties of the Company and its Subsidiaries complies with all applicable codes, laws and regulations (including building and zoning codes, laws and
regulations and laws relating to access to such properties), except for such failures to comply that would not, individually or in the aggregate, reasonably be expected to interfere in any material respect with the use made and proposed to be made
of such property by the Company and its Subsidiaries or otherwise have a Material Adverse Effect. None of the Company or its Subsidiaries has received from any Governmental Entities any notice of any condemnation of, or zoning change affecting, the
properties of the Company and its Subsidiaries, and the Company knows of no such condemnation or zoning change which is threatened, except for such that would not reasonably be expected to interfere in any material respect with the use made and
proposed to be made of such property by the Company and its Subsidiaries or otherwise have a 

  
 17 

	 	
Material Adverse Effect, individually or in the aggregate. The Company and its Subsidiaries have good and marketable title to all personal property owned by them that is material to the business
of the Company and the Company Subsidiaries, in each case free and clear of all liens, encumbrances and defects except such as do not materially affect the value of such property and do not interfere with the use made and proposed to be made of such
property by the Company and its Subsidiaries. 

  

	(n)	 Anti-Corruption, Anti-Money Laundering, and Economic Sanctions Compliance. 

 

	(i)	 (i) None of the Company or any Company Subsidiary or affiliate, or any director, officer, or employee thereof,
or, to the Company’s knowledge, any agent or representative of the Company or any Company Subsidiary or affiliate, has taken or will take any action in furtherance of an offer, payment, promise to pay, or authorization or approval of the
payment, giving or receipt of money, property, gifts or anything else of value, directly or indirectly, to any government official (including any officer or employee of a government or government-owned or controlled entity or of a public
international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office) (“Government Official”) in order to
influence official action, or to any person in violation of any applicable anti-corruption laws; (ii) the Company and each Company Subsidiary and their respective affiliates have conducted their businesses in compliance with applicable
anti-corruption laws and have instituted and maintained and will continue to maintain policies and procedures reasonably designed to promote and achieve compliance with such laws and with the representations and warranties contained herein; and
(iii) neither the Company nor any Company Subsidiary will use, directly or indirectly, the proceeds of the offering in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of
value, to any person in violation of any applicable anti-corruption laws. 

  

	(ii)	 The operations of the Company and each Company Subsidiary are and have been conducted at all times in material
compliance with all applicable financial recordkeeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and
Obstruct Terrorism Act of 2001 (USA PATRIOT Act), and the applicable anti-money laundering statutes of jurisdictions where the Company and each Company Subsidiary conduct business, the rules and regulations thereunder and any related or similar
rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the “Anti-Money Laundering Laws”), and no action, suit or proceeding by or before any court or governmental agency,
authority or body or any arbitrator involving the Company or any Company Subsidiary with respect to the Anti-Money Laundering Laws is pending or, to the best knowledge of the Company, threatened. 

 

	(iii)	 None of the Company or any Company Subsidiary, or any director, officer, or employee thereof, or, to the
Company’s knowledge, any agent, affiliate or representative of the Company or any Company Subsidiary, is a Person that is, or is owned or controlled by one or more Persons that are: 

  
 18 

	(A)	 the subject of any sanctions administered or enforced by the U.S. Department of the Treasury’s Office of
Foreign Assets Control, the United Nations Security Council, the European Union, Her Majesty’s Treasury, or other relevant sanctions authority (collectively, “Sanctions”), or 

 

	(B)	 located, organized or resident in a country or territory that is the subject of Sanctions (as of the date of
this Agreement, the so–called Donetsk People’s Republic, the so–called Luhansk People’s Republic, the Crimea Region of Ukraine, Cuba, Iran, North Korea and Syria). 

 

	(iv)	 The Company will not, directly or indirectly, use the proceeds of the offering, or lend, contribute or
otherwise make available such proceeds to any Subsidiary, joint venture partner or other Person: 

  

	(A)	 to fund or facilitate any activities or business of or with any Person or in any country or territory that, at
the time of such funding or facilitation, is the subject of Sanctions; or 

  

	(B)	 in any other manner that will result in a violation of Sanctions by any Person (including any Person
participating in the offering, whether as underwriter, advisor, investor or otherwise). 

  

	(v)	 The Company and each Company Subsidiary have not knowingly engaged in, are not now knowingly engaged in, and
will not knowingly engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions. 

 

	(o)	 Intellectual Property. Except to the extent it would not be reasonably expected to have a Material
Adverse Effect: (i) the Company and each Company Subsidiary own or have a valid license to use any and all patents, inventions, copyrights, know how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential
information, processes or procedures), trademarks, service marks, trade names, domain names, software, data and other worldwide intellectual property or similar proprietary rights, including any and all registrations and applications for
registration thereof and any and all goodwill associated therewith (collectively, “Intellectual Property Rights”), in each case, used in or reasonably necessary to the conduct of their businesses as currently conducted;
(ii) the Intellectual Property Rights owned or purported to be owned by the Company or any Company Subsidiary (the “Company Owned Intellectual Property Rights”), are solely and exclusively owned by the Company or the Company
Subsidiaries, in each case free and clear of all liens, defects or similar encumbrances or other restrictions, other than non-exclusive licenses granted in the ordinary course of business, (iii) the
Company Owned Intellectual Property Rights and, to the Company’s knowledge, the Intellectual Property Rights licensed to the Company or any Company Subsidiary, are valid, subsisting and enforceable, and there is no pending or, to the
Company’s knowledge, threatened action, suit, proceeding or claim by a third party (A) challenging the validity, scope or enforceability of any such Intellectual Property Rights or (B) alleging that the Company or any Company
Subsidiary has infringed, misappropriated or violated any Intellectual Property Rights of any third party; (iv) neither the Company nor any Company Subsidiary has received any written notice alleging any infringement, misappropriation or other
violation of Intellectual Property Rights; (v) to the Company’s knowledge, no third party is infringing, misappropriating or otherwise violating or has infringed, misappropriated or otherwise violated, any Company Owned Intellectual
Property Rights; (vi) neither the Company nor any Company Subsidiary infringes, misappropriates or 

  
 19 

	 	
otherwise violates, or has infringed, misappropriated or otherwise violated, any Intellectual Property Rights; (vii) all employees or contractors engaged in the development of Intellectual
Property Rights on behalf of the Company or any Company Subsidiary have executed an invention assignment agreement whereby such employees or contractors presently assign all of their right, title and interest in and to such Intellectual Property
Rights to the Company or a Company Subsidiary, and to the Company’s knowledge no such agreement has been breached or violated; and (viii) the Company and the Company Subsidiaries use, and have used, commercially reasonable efforts to
appropriately maintain the confidentiality of all information intended to be maintained as a trade secret (including proprietary confidential software source code). 

 

	(p)	 Open Source Software. Except to the extent it would not be reasonably expected to have a Material
Adverse Effect, (i) the Company and the Company Subsidiaries use and have used any and all software and other materials distributed under a “free,” “open source,” or similar licensing model (including but not limited to the
MIT License, Apache License, GNU General Public License, GNU Lesser General Public License and GNU Affero General Public License) (“Open Source Software”) in compliance with all license terms applicable to such Open Source Software;
and (ii) neither the Company nor any Company Subsidiary uses or distributes or has used or distributed any Open Source Software in any manner that requires or has required (A) the Company or any Company Subsidiary to permit reverse
engineering of any software code or other technology owned by the Company or any Company Subsidiary or (B) any software code or other technology owned by the Company or any Company Subsidiary to be (1) disclosed or distributed in source
code form, (2) licensed for the purpose of making derivative works or (3) redistributed at no charge. 

  

	(q)	 Data Security; Privacy. The Company and each Company Subsidiary: (i) have complied and are
presently in compliance in all material respects with all internal and external written privacy policies, contractual obligations, applicable laws, statutes, judgments, orders, rules and regulations of any court or arbitrator or other governmental
or regulatory authority and any other applicable legal obligations, in each case, relating to the collection, use, transfer, import, export, storage, protection, disposal, disclosure or other processing by or on behalf of the Company or any Company
Subsidiary of personal data, personal information, personally identifiable information, and any similar term as defined by applicable law (“Data Security Obligations”, and such data and information, “Personal
Data”); (ii) maintain and have maintained commercially reasonable policies and procedures designed to ensure the Company’s, and the Company Subsidiaries’ compliance with the Data Security Obligations except to the extent it
would not be reasonably expected to have a Material Adverse Effect, (iii) have not received any notification of or complaint regarding, and are unaware of any other facts that, individually or in the aggregate, would reasonably indicate non-compliance with any Data Security Obligation. There is no action, suit, investigation or proceeding by or before any court or governmental agency or authority pending or threatened in writing against the Company
or any Company Subsidiary alleging non-compliance with any Data Security Obligation. 

  

	(r)	 Information Technology Systems and Data. Except to the extent it would not be reasonably expected to
have a Material Adverse Effect, the information technology assets, equipment, computers, systems, networks, hardware, software, internet websites, applications, data and databases (including the Personal Data, the data of their respective customers,
employees, 

  
 20 

	 	
suppliers, vendors and any other third party data maintained, processed or transmitted by or on behalf of the Company and the Company Subsidiaries) used by or on behalf of the Company and Company
Subsidiaries (collectively, “IT Systems and Data”) are reasonably adequate for, and operate and perform as required in connection with, the operation of the businesses of the Company and the Company Subsidiaries as currently
conducted, free and clear of all bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company and each Company Subsidiary take and have taken all reasonable technical and organizational measures necessary to protect
the IT Systems and Data. Without limiting the foregoing, the Company and the Company Subsidiaries have used commercially reasonable efforts to establish and maintain, and have established, maintained, implemented and complied with, reasonable
information technology, information security, cyber security and data protection controls, policies and procedures, including oversight, access controls, encryption, technological and physical safeguards and business continuity/disaster recovery and
security plans, consistent with industry standards and practices, that are designed to protect against and prevent the breach, destruction, loss, unauthorized distribution, use, access, disablement, misappropriation or modification, or any other
compromise or misuse, in each case, of or relating to any IT Systems and Data (“Breach”). There has been no Breach, and the Company and the Company Subsidiaries have not been notified of and have no knowledge of any event or
condition that would reasonably be expected to result in, any Breach except as would not be reasonably expected to have a Material Adverse Effect. 

  

	(s)	 Environmental Laws. 

 

	(i)	 The Company and each Company Subsidiary (i) are in compliance with any and all applicable foreign,
federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (“Environmental Laws”), (ii) have received
all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii) are in compliance with all terms and conditions of any such permit, license or approval, except where
such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not, singly or in the aggregate, reasonably
be expected to have a Material Adverse Effect. 

  

	(ii)	 There are no costs or liabilities associated with Environmental Laws (including, without limitation, any
capital or operating expenditures required for clean-up, closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints on operating activities and any
potential liabilities to third parties) which would, singly or in the aggregate, reasonably be expected to have a Material Adverse Effect. 

  

	(t)	 Labor Disputes. No material labor dispute with the employees of the Company or any Company Subsidiary
exists, or, to the knowledge of the Company, is imminent; and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any of its principal suppliers, manufacturers or contractors that could, singly or
in the aggregate, have a Material Adverse Effect. 

  
 21 

	(u)	 Investment Company Act. The Company is not, and immediately after receipt of payment for the Notes at
the Closing and the transactions contemplated by the other Transaction Agreements, will not be, required to register as an “investment company” within the meaning of the Investment Company Act of 1940, as amended. 

 

	(v)	 Insurance. The Company and each Company Subsidiary are insured by insurers of recognized financial
responsibility against such losses and risks and in such amounts as, in the Company’s reasonable judgment, are prudent and customary in the businesses in which they are engaged; neither the Company nor any Company Subsidiary has been refused
any insurance coverage sought or applied for; and neither the Company nor any Company Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar
coverage from similar insurers as may be necessary to continue its business at a cost that would not, singly or in the aggregate, reasonably be expected to have a Material Adverse Effect. 

 

	(w)	 Certificates; Authorizations. The Company and each Company Subsidiary possess all certificates,
authorizations and permits issued by the appropriate federal, state or foreign regulatory authorities necessary to conduct their respective businesses, and neither the Company nor any Company Subsidiary has received any notice of proceedings
relating to the revocation or modification of any such certificate, authorization or permit which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a Material Adverse Effect. 

 

	(x)	 Internal Controls. The Company and each Company Subsidiary maintain a system of internal accounting
controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with U.S. GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets
is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Since the end of the Company’s most recent audited fiscal year, there has been (i) no material weakness in the
Company’s internal control over financial reporting (whether or not remediated) and (ii) no change in the Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect,
the Company’s internal control over financial reporting, in each case, other than as disclosed in any Company Reports. 

  

	(y)	 Taxes and Tax Returns. The Company and each Company Subsidiary have filed all federal, state, local and
foreign Tax Returns required to be filed through the date of this Agreement or have requested extensions thereof (except where the failure to file would not, singly or in the aggregate, have a Material Adverse Effect) and have paid all taxes
required to be paid thereon (except for cases in which the failure to file or pay would not, singly or in the aggregate, have a Material Adverse Effect, or, except as currently being contested in good faith and for which reserves required by U.S.
GAAP have been created in the financial statements of the Company), and no tax deficiency has been determined adversely to the Company or any Company Subsidiary which, singly or in the aggregate, has had (nor does the Company nor any Company
Subsidiary have any notice or knowledge of any tax deficiency which could reasonably be expected to be determined adversely to the Company or the Company Subsidiaries and which could reasonably be expected to have) a Material Adverse Effect.

  
 22 

	(z)	 Statistical Data. Neither the Company, the Guarantors nor any Company Subsidiary has any securities
rated by any “nationally recognized statistical rating organization,” as such term is defined in Section 3(a)(62) of the Exchange Act. 

  

	(aa)	 Brokers and Finders. The Company has not retained, utilized or been represented by, or otherwise become
obligated to, any broker, placement agent, financial advisor or finder in connection with the transactions contemplated by this Agreement or the other Transaction Agreements whose fees the Purchasers would be required to pay. 

 

	(bb)	 Registration Statement Eligibility. The Company is eligible to file a registration statement on Form S-3 under the rules and requirements of the SEC. 

  

	(cc)	 Not an Affiliate. None of the Company or the Guarantors as of the date of this Agreement has any reason
to believe that, as of the date hereof, any Purchaser is an Affiliate of the Company (for purposes of Rule 144). 

  

	(dd)	 Subsidiary Guarantors. The entities that are party to the Indenture as Guarantors are all of the
Subsidiaries of the Company that are not (individually or in the aggregate) “Immaterial Subsidiaries” as defined in the Indenture. 

  

	(ee)	 No Additional Representations. 

 

	(i)	 The Company and the Guarantors acknowledge that each Purchaser makes no representation or warranty as to any
matter whatsoever except as expressly set forth in Section 3.02 or in any certificate delivered by such Purchaser pursuant to this Agreement, and neither the Company and the Guarantors have relied on or been induced by such information or any
other representations or warranties (whether express or implied or made orally or in writing) not expressly set forth in Section 3.02 or in any certificate delivered by such Purchaser pursuant to this Agreement. 

 

	(ii)	 The Company and the Guarantors acknowledge and agree that, except for the representations and warranties
expressly set forth in Section 3.02 or in any certificate delivered by each Purchaser pursuant to this Agreement, (i) no person has been authorized by such Purchaser to make any representation or warranty relating to such Purchaser or
otherwise in connection with the transactions contemplated hereby, and if made, such representation or warranty must not be relied upon by the Company or the Guarantors as having been authorized by such Purchaser, and (ii) any materials or
information provided or addressed to the Company, the Guarantors or any of their Affiliates or representatives are not and shall not be deemed to be or include representations or warranties of such Purchaser unless any such materials or information
are the subject of any express representation or warranty set forth in Section 3.02 of this Agreement or in any certificate delivered by such Purchaser pursuant to this Agreement. 

Section 3.02. Representations and Warranties of Each Purchaser. Each Purchaser, severally and not jointly, represents and warrants to, and agrees
with, the Company, as of the date hereof and as of the Closing Date and the Closing Date, as follows: 

  
 23 

	(a)	 Organization; Ownership. Such Purchaser is duly organized, validly existing and in good standing (to the
extent that the concept of “good standing” is recognized by the applicable jurisdiction) under the laws of its jurisdiction of organization and has all requisite power and authority to own, operate and lease its properties and to carry on
its business as it is being conducted on the date of this Agreement. 

  

	(b)	 Authorization; Sufficient Funds; No Conflicts. 

 

	(i)	 Such Purchaser has the power and authority to execute and deliver this Agreement and to consummate the purchase
of the Notes. The execution, delivery and performance by such Purchaser of the Transaction Agreements to which it is a party and the consummation of the transactions contemplated thereby have been duly authorized by all necessary action by such
Purchaser. No other proceedings on the part of such Purchaser are necessary to authorize the execution, delivery and performance by such Purchaser of the Transaction Agreements to which it is a party and consummation of the transactions contemplated
thereby. This Agreement has been duly and validly executed and delivered by such Purchaser. Assuming this Agreement constitutes the valid and binding obligation of the Company, this Agreement is a valid and binding obligation of such Purchaser,
enforceable against it in accordance with its terms, subject to the limitation of such enforcement by the Enforceability Exceptions. 

  

	(ii)	 Such Purchaser has as of the date hereof, and will have as of the Closing, cash in immediately available funds
or uncalled and unrestricted capital commitments in excess of the Purchase Price payable by it. 

  

	(iii)	 The execution, delivery and performance of the Transaction Agreements to which such Purchaser is a party by
such Purchaser, the consummation by such Purchaser of the transactions contemplated thereby, and the compliance by such Purchaser with any of the provisions thereof will not conflict with, violate or result in a breach of any provision of, or
constitute a default under, or result in the termination of or accelerate the performance required by, or result in a right of termination or acceleration under, (A) any provision of such Purchaser’s organizational documents, (B) any
mortgage, note, indenture, deed of trust, lease, license, loan agreement or other agreement binding upon such Purchaser or any of its Affiliates or (C) any permit, license, judgment, order, decree, ruling, injunction, statute, law, ordinance,
rule or regulation applicable to such Purchaser or any of its Affiliates, other than in the cases of clauses (B) and (C) as would not reasonably be expected to materially and adversely affect or delay the consummation of the Transactions.

  

	(c)	 Consents and Approvals. No consent, approval, order or authorization of, or registration, declaration or
filing with, or exemption or review by, any Governmental Entity is required on the part of such Purchaser in connection with the execution, delivery and performance by such Purchaser of this Agreement, and the consummation by such Purchaser of the
Transactions to which it is a party, except for any required filings or approvals under the HSR Act or any foreign antitrust or competition laws, requirements or regulations in connection with the issuance of shares of Company Common Stock upon the
conversion of the Notes and any consent, approval, order, authorization, registration, declaration, filing, exemption or review the failure of which to be obtained or made, individually or in the aggregate, would not reasonably be expected to
adversely affect or delay the consummation of the Transactions by such Purchaser. 

  
 24 

	(d)	 Securities Act Representations. Such Purchaser is an accredited investor (as defined in Rule 501 under
the Securities Act) and is aware that the sale of the Notes is being made in reliance on a private placement exemption from registration under the Securities Act and that the Notes may be resold only if registered pursuant to the provisions of the
Securities Act or pursuant to an exemption from such registration. Such Purchaser is acquiring the Notes (and any shares of Company Common Stock issuable upon conversion of the Notes) for its own account, and not with a view toward, or for sale in
connection with, any distribution thereof in violation of any federal or state securities or “blue sky” law, or with any present intention of distributing or selling such Notes (or any shares of Company Common Stock issuable upon
conversion of the Notes) in violation of the Securities Act. Such Purchaser has sufficient knowledge and experience in financial and business matters so as to be capable of evaluating the merits and risks of its investment in such Notes (and any
shares of Company Common Stock issuable upon conversion of the Notes) and is capable of bearing the economic risks of such investment. Such Purchaser has been provided a reasonable opportunity to undertake and has undertaken such investigation and
has been provided with and has evaluated such documents and information as it has deemed necessary to enable it to make an informed and intelligent decision with respect to the execution, delivery and performance of this Agreement. Such Purchaser
has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect to its acquisition of the Notes. 

 

	(e)	 Brokers and Finders. Such Purchaser has not retained, utilized or been represented by, or otherwise
become obligated to, any broker, placement agent, financial advisor or finder in connection with the transactions contemplated by this Agreement whose fees the Company would be required to pay. 

 

	(f)	 No Additional Representations. 

 

	(i)	 Such Purchaser acknowledges that the Company does not make any representation or warranty as to any matter
whatsoever except as expressly set forth in Section 3.01 or in any certificate delivered by the Company pursuant to this Agreement, and specifically (but without limiting the generality of the foregoing), that, except as expressly set forth in
Section 3.01 or in any certificate delivered by the Company pursuant to this Agreement, the Company makes no representation or warranty with respect to (A) any matters relating to the Company, its business, financial condition, results of
operations, prospects or otherwise, (B) any projections, estimates or budgets delivered or made available to such Purchaser (or any of its Affiliates, officers, directors, employees or other representatives) of future revenues, results of
operations (or any component thereof), cash flows or financial condition (or any component thereof) of the Company and its Subsidiaries or (C) the future business and operations of the Company and its Subsidiaries, and such Purchaser has not
relied on or been induced by such information or any other representations or warranties (whether express or implied or made orally or in writing) not expressly set forth in Section 3.01 or in any certificate delivered by the Company pursuant
to this Agreement. 

  

	(ii)	 Such Purchaser has conducted its own independent review and analysis of the business, operations, assets,
liabilities, results of operations, financial condition and prospects of the Company and its Subsidiaries and acknowledges such Purchaser has been provided with sufficient access for such purposes. Such Purchaser acknowledges and agrees that, except
for the 

  
 25 

	 	
representations and warranties expressly set forth in Section 3.01 or in any certificate delivered by the Company or the Guarantors pursuant to this Agreement, (i) no person has been
authorized by the Company or the Guarantors to make any representation or warranty relating to itself or its business or otherwise in connection with the transactions contemplated hereby, and if made, such representation or warranty must not be
relied upon by such Purchaser as having been authorized by the Company or the Guarantors, and (ii) any estimates, projections, predictions, data, financial information, memoranda, presentations or any other materials or information provided or
addressed to such Purchaser or any of its Affiliates or representatives are not and shall not be deemed to be or include representations or warranties of the Company or the Guarantors unless any such materials or information are the subject of any
express representation or warranty set forth in Section 3.01 of this Agreement or in any certificate delivered by the Company or the Guarantors pursuant to this Agreement. 

ARTICLE 4 

ADDITIONAL AGREEMENTS 

Section 4.01. Taking of Necessary Action. Each party hereto agrees to use its reasonable efforts promptly to take or cause to be taken all action
and promptly to do or cause to be done all things necessary, proper or advisable under applicable laws and regulations to consummate and make effective the sale and purchase of the Notes hereunder, subject to the terms and conditions hereof and
compliance with applicable law. In case at any time before or after the Closing any further action is necessary or desirable to carry out the purposes of the sale and purchase of the Notes, the proper officers, managers and directors of each party
to this Agreement shall take all such necessary action as may be reasonably requested by, and the sole expense of, the requesting party. 

Section 4.02. Securities Laws. Each Purchaser acknowledges and agrees that the issuance and sale of the Notes (and the shares of Company Common
Stock that are issuable upon conversion of the Notes) have not been registered under the Securities Act or the securities laws of any state and that they may be sold or otherwise disposed of only in one or more transactions registered under the
Securities Act and, where applicable, such laws, or as to which an exemption from the registration requirements of the Securities Act and, where applicable, such laws, is available. Each Purchaser acknowledges that, except as provided in Article 5
with respect to shares of Company Common Stock and the Notes, such Purchaser has no right to require the Company or any Company Subsidiary to register the shares of Company Common Stock that are issuable upon conversion of the Notes. Each Purchaser
also acknowledges and agrees that the Notes and underlying shares of Company Common Stock may be notated with a restrictive legend, subject to the terms of the Indenture and the Notes. 

Section 4.03. Lost, Stolen, Destroyed or Mutilated Securities. Upon receipt of evidence satisfactory to the Company of the loss, theft,
destruction or mutilation of any certificate for any security of the Company and, in the case of loss, theft or destruction, upon delivery of an undertaking by the holder thereof to indemnify the Company (and, if requested by the Company, the
delivery of an indemnity bond sufficient in the judgment of the Company to protect the Company from any loss it may suffer if a certificate is replaced), or, in the case of mutilation, upon surrender and cancellation thereof, the Company will issue
a new certificate or, at the Company’s option, a share ownership statement representing such securities for an equivalent number of shares or another security of like tenor, as the case may be. 

  
 26 

 Section 4.04. Antitrust Approval. The Company and the Purchasers acknowledge that one or more
filings under the HSR Act or foreign antitrust laws may be necessary in connection with the issuance of shares of Company Common Stock upon conversion. Each Purchaser will promptly notify the Company if any such filing is required on the part of
such Purchaser. To the extent reasonably requested, the Company, such Purchaser and any other applicable Purchaser Affiliate will use reasonable best efforts to cooperate in timely making or causing to be made all applications and filings under the
HSR Act or any foreign antitrust requirements in connection with the issuance of shares of Company Common Stock upon conversion of Notes held by such Purchaser or any Purchaser Affiliate in a timely manner and as required by the law of the
applicable jurisdiction; provided that, notwithstanding anything in this Agreement to the contrary, the Company shall not have any responsibility or liability for failure of such Purchaser or any of its Affiliates to comply with any
applicable law. The Company and each Purchaser shall cooperate, provide all necessary information, and keep each other fully apprised with respect to such filing and regulatory processes. For as long as there are Notes outstanding and owned by a
Purchaser or its Affiliates, the Company shall as promptly as reasonably practicable provide (no more than four (4) times per calendar year) such information regarding the Company and its Subsidiaries as the Purchasers may reasonably request in
order to determine what foreign antitrust requirements may exist with respect to any potential conversion of the Notes. Each party shall be responsible for the payment of the filing fees and any other costs and expenses incurred by it in connection
with any such applications or filings made by such party. 
 Section 4.05. Conversion Price Matters. Prior to the open of trading on the
Business Day immediately following the date of this Agreement, the Company shall issue an initial press release and file a current report on Form 8-K relating to this Agreement in the form mutually agreed upon
by the Company and the Purchasers (such date the press release is issued and Form 8-K are filed, the “Announcement Date”). The Conversion Price in the Indenture shall be calculated as the
lower of (i) (A) the average of the Daily VWAP per share of the Company Common Stock on Nasdaq for each Trading Day during the period (the “VWAP Period”) starting on the first Trading Day immediately following the date of this
Agreement and ending on the seventh Trading Day immediately following the date of this Agreement (determined by calculating the daily volume-weighted average price on each Trading Day during such period without regard to after-hours trading or any
other trading outside of the regular trading session trading hours, the “Average VWAP”) multiplied by (B) 130.0%; and (ii) $9.3340; provided, however, that the Conversion Price shall not be less than $7.8980. The
maximum Conversion Rate in the Indenture shall be calculated based on the Average VWAP. The Company and the Purchasers shall cooperate to agree the “make-whole” table in the Indenture following customary procedures for similar convertible
notes sold by public companies in the United States through nationally recognized investment banks. 
 Section 4.06. Nasdaq Approval.
The Company shall use its reasonable best efforts to cause the shares of Company Common Stock issuable upon conversion of the Notes to be approved for listing on the Nasdaq, subject to official notice of issuance. 

  
 27 

 Section 4.07. DTC Eligibility. The Company shall cause the Notes and the
restricted Company Common Stock to be assigned one or more CUSIPs that are DTC eligible and shall make the Notes available on request to any Purchaser through the facilities of DTC no later than the Closing Date. 

Section 4.08. Authorized and Reserved Company Common Stock. For so long as any Notes are outstanding, the Company
shall cause the authorized capital stock of the Company to include a sufficient number of authorized but unissued shares of Company Common Stock to satisfy the conversion requirements of all Notes then outstanding (giving effect to any adjustment to
the Conversion Rate pursuant to the Notes and assuming upon conversion the only settlement option under the Notes and the Indenture was for settlement in shares of Company Common Stock), and shall reserve and keep available out of its authorized but
unissued shares of Company Common Stock such number of shares thereof for issuance upon conversion of the Notes. 
 Section 4.09. Hedging. Each
Purchaser agrees that beginning on the date of this Agreement and ending on the date of termination of the VWAP Period, neither such Purchaser, nor any of its Affiliates, agents or representatives, shall in any manner whatsoever sell, offer to sell,
contract or agree to sell, hypothecate, pledge, grant any option to purchase or otherwise dispose of or agree to dispose of, directly or indirectly, or establish or increase a put equivalent position or liquidate or decrease a call equivalent
position within the meaning of Section 16 of the Exchange Act and the rules and regulations of the SEC promulgated thereunder, any shares of Company Common Stock or enter into any swap or arrangement that transfers to another, in whole or in
part, any of the economic consequences of ownership of Company Common Stock, whether any such transaction is to be settled by delivery of such securities, in cash or otherwise with respect to a number of shares of Company Common Stock that on any
Trading Day during such period exceeds 3,000,000 shares. 
 Section 4.10. Indemnification. 

 

	(a)	 Each Purchaser, its Affiliates and its and their respective officers, directors, members, employees, managers,
general partners, advisors and agents (each, an “Indemnitee”) shall be indemnified to the fullest extent permitted by law by the Company, jointly and severally, for any and all Losses to which such Indemnitees may become subject as
a result of, arising in connection with, or relating to any actual or threatened claim, suit, action, arbitration, cause of action, complaint, allegation, criminal prosecution, investigation, inquiry, demand letter, or proceeding, whether at law or
at equity, direct or derivative and whether public or private, before or by any Governmental Entity, any arbitrator or other tribunal (each, and including any appeals therefrom, an “Action”) by any third party (including, without
limitation, any stockholder of the Company or any regulator and including Losses arising from Actions not directly against an Indemnitee, such as witness expenses or responding to inquiries from a Governmental Entity) related to the Transactions;
provided that the Company shall not be liable to indemnify any Indemnitee for any such Losses to the extent that such Losses (i) have resulted from a Purchaser’s breach of this Agreement, (ii) related to any transaction or
arrangement, including any financing or hedging arrangement or trading in Company Common Stock, of such Purchaser or its Affiliates in connection with the applicable Purchaser’s or its Affiliates’ investment in the Notes or (iii) have
resulted from an Indemnitee’s willful misconduct or fraud in connection with the Transactions; provided, further, that the Company shall not be liable to indemnify an

  
 28 

	 	
Indemnitee or its Affiliates and its and their respective officers, directors, members, employees, managers, general partners, advisors and agents under this Section 4.10 unless such
Indemnitee provides notice of an Action for which indemnification is sought no later than six (6) months following the Closing Date, in which case the Company’s indemnification obligations under this Section 4.10 shall cover such
Action and any appeals therefrom. The parties agree, for the avoidance of doubt, that this Section 4.10 shall not apply to any matter for which indemnification is otherwise provided in Section 5.05. 

 

	(b)	 Each Indemnitee shall give the Company prompt written notice (an “Indemnification Notice”) of
any Action it has actual knowledge of that might give rise to Losses for which an Indemnitee would reasonably be likely to be entitled to indemnification under this Section 4.10, which notice shall set forth a description of those elements of
such Action of which such Indemnitee has knowledge and promptly deliver to the Company any complaints such Action or other documents provided to such Indemnitee in connection with; provided, that any delay or failure to give such Indemnification
Notice shall not affect the indemnification obligations of the Company hereunder except to the extent the Company are materially prejudiced by such delay or failure. 

 

	(c)	 The Company shall have the right, exercisable by written notice to the applicable Indemnitee within thirty
(30) days of receipt of the applicable Indemnification Notice, to select counsel to defend and control the defense of any third party claim set forth in such Indemnification Notice and the Company shall pay all fees and expenses of such
counsel; provided, that the Company shall not be entitled to so select counsel or control the defense of any claim to the extent that (i) such claim seeks primarily non-monetary or injunctive relief
against the Indemnitee or alleges any violation of criminal law, (ii) the Company does not, subsequent to its assumption of such defense in accordance with this clause (c), conduct the defense of such claim in good faith, (iii) any of the
Indemnitees reasonably determines upon the advice of counsel that representation of all such Indemnitees by the same counsel would be prohibited by applicable codes of professional conduct, or (iv) in the event that, based on the reasonable
advice of counsel for the applicable Indemnitee, there are one or more material defenses available to the applicable Indemnitee that are not available to other defendants. If the Company does not assume the defense of any third party claim in
accordance with this clause (c), the applicable Indemnitee may continue to defend such claim at the sole cost of the Company and the Company may still participate in, but not control, the defense of such third party claim at the Company’s sole
cost and expense. In no event shall the Company, in connection with any Action or separate but substantially similar Actions arising out of the same general allegations, be liable for the fees and expenses of more than one separate firm of attorneys
at any time for all Indemnitees chosen by the applicable Purchaser together with its Affiliates, and one separate firm of local counsel, in addition to regular counsel, to the extent required in order to effectively defend the Action.

  

	(d)	 No Indemnitee shall consent to a settlement of, or the entry of any judgment arising from, any claim for which
such Indemnitee is entitled to indemnification pursuant to this Section 4.10, without the prior written consent of the Company (such consent not to be unreasonably withheld, conditioned or delayed). Except with the prior written consent of the
applicable Indemnitee, the Company, in the defense of any claim for which such Indemnitee is entitled to indemnification pursuant to this Section 4.10, shall not consent to the entry of any judgment or enter into any settlement unless such
settlement includes (i) an unconditional release of such indemnified party from all liability on claims that are the subject matter of such proceeding and (ii) does not 

  
 29 

	 	
include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party. In any such third party claim where the Company has assumed control
of the defense thereof pursuant to clause (c), the Company shall keep the applicable Indemnitee reasonably informed as to the status of such claim at all stages thereof (including all settlement negotiations and offers), promptly submit to such
Indemnitee copies of all pleadings, responsive pleadings, motions and other similar legal documents and paper received or filed in connection therewith, permit such Indemnitee and their respective counsels to confer with the Company and its counsel
with respect to the conduct of the defense thereof, and permit such Indemnitee and their respective counsel a reasonable opportunity to review all legal papers to be submitted prior to their submission; provided that the Company shall not be
obligated to provide materials, documents or information the disclosure of which would reasonably be likely to jeopardize the attorney-client privilege between the Company and its counsel or violate applicable law. 

Section 4.11. Certain Tax Matters. The Company acknowledges its obligation to determine whether the Notes are a “section 871(m)
transaction” in accordance with Treasury Regulations Section 1.871-15(p) and will inform each Purchaser of its determination within 10 days of the Closing Date and fulfill all other obligations of
the “responsible party” within the meaning of that section. Notwithstanding anything herein to the contrary, the Company shall have the right to deduct and withhold from any payment or distribution made with respect to the Notes (or the
issuance of shares of Company Common Stock upon conversion or repurchase by the Company of the Notes) such amounts as are required to be deducted or withheld with respect to the making of such payment or distribution (or issuance) under any
applicable Tax law. To the extent that any amounts are so deducted or withheld, such deducted or withheld amounts shall be treated for all purposes of this Agreement as having been paid to the person in respect of which such deduction or withholding
was made. In the event the Company previously remitted any amounts to a Governmental Entity on account of Taxes required to be deducted or withheld in respect of any payment or distribution (or deemed distribution) on any Notes, the Company shall be
entitled to effect any such amounts against any amounts otherwise payable in respect of such Notes (or the issuance of shares of Company Common Stock upon conversion or repurchase by the Company of the Notes). 

ARTICLE 5 

REGISTRATION RIGHTS 

Section 5.01. Registration Statement. 
  

	(a)	 As soon as reasonably practicable after the issuance of the Notes, the Company will use reasonable efforts to
prepare and file and use reasonable efforts to cause to be declared effective or otherwise become effective pursuant to the Securities Act (such date of effectiveness, the “Registration Date”) a Registration Statement or
post-effective amendment to an existing Registration Statement in order to register the issuance of the Registrable Securities (which shall cover the maximum number of shares of Company Common Stock issuable assuming the combination of all of the
following: (x) full “physical” settlement of conversions of the Notes into shares of Company Common Stock and (y) the maximum “make-whole” adjustment to the conversion rate, in each case, in accordance with the terms of
the Indenture) and to provide for resales of the Registrable Securities to be made on a delayed or continuous basis pursuant to Rule 415 under the Securities Act (subject to the availability of a Registration Statement on

  
 30 

	 	
Form S-3 or any successor form thereto), which Registration Statement will (except to the extent the SEC objects in written comments upon the SEC’s
review of such Registration Statement) include a plan of distribution and selling stockholder disclosure reasonably requested by a Purchaser. In addition, the Company will from time to time, after the initial Registration Statement has been declared
effective, use reasonable efforts to file such additional Registration Statements to cover resales of any Registrable Securities that are not registered for resale pursuant to a pre-existing Registration
Statement, including, without limitation, PIK Shares, and will use its reasonable efforts to cause such Registration Statement to be declared effective or otherwise to become effective under the Securities Act and will use its reasonable efforts to
keep the Registration Statement continuously effective under the Securities Act at all times until the Registration Termination Date. The Company shall not be allowed to elect to pay PIK Interest on the Notes using the Capitalization Method unless a
Registration Statement covering the maximum number of additional shares of Company Common Stock that may be issuable pursuant to conversions of the Notes for every interest payment date from the date of such proposed payment of PIK Interest until
maturity (such shares, “PIK Shares”) is effective and available for use and is expected to remain effective in accordance with the provisions of the preceding sentence. Any Registration Statement filed pursuant to this Article 5
shall cover only Registrable Securities, shall be on Form S-3 (or a successor form) if the Company is eligible to use such form and shall be an automatically effective Registration Statement if the Company is
a WKSI. 

  

	(b)	 Subject to the provisions of Section 5.02, and further subject to the availability of a Registration
Statement on Form S-3 (or any successor form thereto) to the Company pursuant to the Securities Act and the rules and interpretations of the SEC, the Company will use its reasonable efforts to keep the
Registration Statement (or any replacement Registration Statement) continuously effective until the earlier of (such earlier date, the “Registration Termination Date”): (i) the date on which all Registrable Securities covered by the
Registration Statement have been sold thereunder in accordance with the plan and method of distribution disclosed in the prospectus included in the Registration Statement, (ii) there otherwise cease to be any Registrable Securities,
(iii) following the maturity date of the Notes and full settlement of principal and interest in accordance with the terms of the Indenture, the Registrable Securities represent less than $25 million by value in the aggregate and
(iv) one (1) year after the maturity date of the Notes. 

  

	(c)	 During such period of time that the Company ceases to be eligible to file or use a Registration Statement on
Form S-3 (or any successor form thereto), upon the written request of any holder of Registrable Securities, the Company shall use its reasonable efforts to file a Registration Statement on Form S-1 (or any successor form) under the Securities Act covering the Registrable Securities of the requesting party and use reasonable efforts to cause such Registration Statement to be declared effective pursuant to
the Securities Act as soon as reasonably practicable after filing thereof and use reasonable efforts to file and cause to become effective such amendments thereto as are necessary in order to keep such Registration Statement available for no less
than 60 days after its effective date. When the Company regains ability to file a Registration Statement on Form S-3 covering the Registrable Securities it shall use reasonable efforts to do so as promptly as
practicably do so in accordance with Section 5.01(a). 

 Section 5.02. Registration Limitations and Obligations. 

  
 31 

	(a)	 Subject to Section 5.01, the Company will use reasonable efforts to prepare such supplements or amendments
(including a post-effective amendment), if required by applicable law, to each applicable Registration Statement and file any other required document so that such Registration Statement will be Available at all times during the period for which such
Registration Statement is, or is required pursuant to this Agreement to be, effective; provided, that no such supplement, amendment or filing will be required during a Blackout Period. Notwithstanding anything to the contrary contained in
this Agreement, the Company shall be entitled, from time to time, by providing written notice to the holders of Registrable Securities, to require such holders to suspend the use of the prospectus for sales of Registrable Securities under the
Registration Statement during any Blackout Period; provided, for purposes of this Section 5.02, the Company shall only be obligated to provide written notice to any holder or Beneficial Owner of Registrable Securities of any such
Blackout Period if such holder or Beneficial Owner has specified in writing to the Company for purposes of receiving such notice such holder’s or Beneficial Owner’s address and contact information. No sales may be made under the applicable
Registration Statement during any Blackout Period of which the holders of Registrable Securities have received notice. In the event of a Blackout Period, the Company shall notify each holder of Registrable Securities promptly upon each of the
commencement and the termination of each Blackout Period, which notice of termination shall be delivered to each holder of Registrable Securities no later than the close of business of the last day of the Blackout Period. In connection with the
expiration of any Blackout Period and without any further request from a holder of Registrable Securities, the Company to the extent necessary and as required by applicable law shall as promptly as reasonably practicable prepare supplements or
amendments, including a post-effective amendment, to the Registration Statement or the prospectus, or any document incorporated therein by reference, or file any other required document so that the Registration Statement will be Available. A
Blackout Period shall be deemed to have expired when the Company has notified the holders of Registrable Securities that the Blackout Period is over and the Registration Statement is Available. Notwithstanding anything in this Agreement to the
contrary, the absence of an Available Registration Statement at any time from and after the Registration Date shall be considered a Blackout Period and subject to the limitations therein. 

 

	(b)	 At any time that a Registration Statement is effective and prior to the Registration Termination Date, if a
holder of Registrable Securities delivers a notice to the Company (a “Take-Down Notice”) stating that it, together with any other Persons, intend to sell at least $50,000,000 in aggregate of Registrable Securities held by such
holder and such other Persons, in each case, pursuant to the Registration Statement, then, no more than two (2) times in any twelve (12)-month period, the Company shall amend or supplement the Registration Statement as may be necessary and to
the extent required by law so that the Registration Statement remains Available in order to enable such Registrable Securities to be distributed in an Underwritten Offering. In connection with any Underwritten Offering of Registrable Securities for
which a holder delivers a Take-Down Notice and satisfies the dollar thresholds set forth in first sentence above, and where the Take-Down Notice contemplates marketing efforts not to exceed twenty-four (24) hours by the Company and the
underwriters, the Company will use reasonable efforts to cooperate and make its senior officers available for participation in such marketing efforts (which marketing efforts will not, for the avoidance of doubt, include a “road show”
requiring such officers to travel outside of the city in which they are primarily located). The Company shall select the underwriters (including the managing underwriters) for each Underwritten Offering; provided that the underwriters shall
be reasonably acceptable to the holder of 

  
 32 

	 	
Registrable Securities that delivered the applicable Take-Down Notice. The Company shall select the counsel for the underwriters; provided that such counsel shall be reasonably acceptable
to the managing underwriters and the holder of Registrable Securities that delivered the applicable Take-Down Notice. Such holder shall determine the pricing of the Registrable Securities offered pursuant to any such Registration Statement,
including the underwriting discount and fees payable by such holder to the underwriters in such Underwritten Offering. Such holder shall reasonably determine the timing of any such registration and sale. Such holder shall determine the applicable
underwriting discount and other financial terms, and such holder of the Registrable Securities sold in the Underwritten Offering shall be solely responsible for all such discounts and fees payable to such underwriters in such Underwritten Offering.
Without the consent of the applicable holder of Registrable Securities subject to an Underwritten Offering, no Underwritten Offering pursuant to this Agreement shall include any securities other than Registrable Securities. 

 

	(c)	 In connection with an Underwritten Offering, the Company and its directors and officers shall, to the extent
requested by managing underwriters of such a distribution, be subject to a customary lockup agreement with a restricted period of the same length of time as such holder agrees with the managing underwriters (but not to exceed 90 days) during which
the Company may not issue or transfer, and its officers and directors may not transfer, shares of Company Common Stock or any securities exchangeable or exercisable for, or convertible into, shares of Company Common Stock, subject to customary
carve-outs agreed with the managing underwriters, which may include, but are not limited to: (i) issuances pursuant to the Company’s employee or director stock plans and issuances of shares upon the exercise of options or other equity
awards under such stock plans, (ii) sales in connection with the settlement of equity awards to cover tax withholding obligations, and (iii) sales under trading plans pursuant to Rule 10b5-1, and
(iv) in connection with acquisitions, joint ventures and other strategic transactions (which, in the case of this clause (iv), would not exceed up to 10% of the outstanding Company Common Stock at the time of such Underwritten Offering).

  

	(d)	 In addition to the registration rights provided in this Section 5.02, holders of the Notes shall have
analogous rights to sell such securities in a marketed offering under Rule 144A through one or more initial purchasers on a firm-commitment basis, on the terms, subject to the conditions and using procedures that are substantially equivalent to
those specified in this Section 5.02 and Section 5.03, mutatis mutandis. The Company agrees to use its reasonable efforts to cooperate to effect any such sales under such Rule 144A; provided that nothing in this
Section 5.02(d) shall impose any additional or more burdensome obligations on the Company than would apply under this Section 5.02 and Section 5.03, in each case, mutatis mutandis in respect of a registered Underwritten
Offering, or require that the Company take any actions that it would not be required to take in a substantially similar Underwritten Offering of such Notes. 

Section 5.03. Registration Procedures. 
  

	(a)	 If and whenever the Company is required to use reasonable efforts to effect the registration of any Registrable
Securities under the Securities Act and in connection with any distribution of Registrable Securities pursuant thereto as provided in this Agreement (including any sale referred to in any Take-Down Notice), the Company shall as promptly as
reasonably practicable, subject to the other provisions of this Agreement: 

  
 33 

	(i)	 use reasonable efforts to prepare and file with the SEC a Registration Statement to effect such registration in
accordance with the intended method or methods of distribution of such securities and thereafter use reasonable efforts to cause such Registration Statement to become and remain effective pursuant to the terms of this Article 5; provided,
however, that the Company may discontinue any registration of its securities which are not Registrable Securities at any time prior to the effective date of the Registration Statement relating thereto; provided, further, that before filing
such registration statement or any amendments or supplements thereto, including any prospectus supplements in connection with a sale referred to in a Take-Down Notice, the Company will furnish to the holders which are including Registrable
Securities in such registration (“Selling Holders”) and the lead managing underwriters, if any, copies of all such documents proposed to be filed, which documents will be subject to the review and reasonable comment (which comments
will be considered in good faith by the Company) of the counsel (if any) to such holders and counsel (if any) to such underwriters, and other documents reasonably requested by any such counsel, including any comment letter from the SEC, and, if
requested by any such counsel, provide such counsel and the lead managing underwriters, if any, reasonable opportunity to participate in the preparation of such Registration Statement and each prospectus (including any prospectus supplement)
included or deemed included therein and such other opportunities to conduct a customary and reasonable due diligence investigation (in the context of a registered underwritten offering) of the Company, including reasonable access to (including
responses to any reasonable inquiries by the lead managing underwriters and their counsel) the Company’s books and records, officers, accountants and other advisors; provided that the same occurs during normal business hours after
reasonable notice and does not materially interfere with the business of the Company; provided further that such persons shall first agree in writing with the Company that any information that is reasonably designated by the Company as
confidential at the time of delivery shall be kept confidential by such persons subject to customary exceptions; 

  

	(ii)	 prepare and file with the SEC such amendments and supplements to such Registration Statement and the prospectus
used in connection therewith as may be necessary and to the extent required by applicable law to keep such Registration Statement effective and Available pursuant to the terms of this Article 5; 

 

	(iii)	 if requested by the lead managing underwriters, promptly include in a prospectus supplement or post-effective
amendment such information as the lead managing underwriters, if any, and such holders may reasonably request in order to permit the intended method of distribution of such securities and make all required filings of such prospectus supplement or
such post-effective amendment as soon as reasonably practicable after the Company has received such request; provided, however, that the Company shall not be required to take any actions under this Section 5.03(a)(iii) that are
not, in the opinion of counsel for the Company, in compliance with applicable law; 

  

	(iv)	 furnish to the Selling Holders and each underwriter, if any, of the securities being sold by such Selling
Holders such number of conformed copies of such Registration Statement and of each amendment and supplement thereto, such number of copies of the prospectus and any prospectus supplement contained in or deemed part of such Registration Statement
(including each preliminary prospectus supplement) utilized in connection therewith and any other prospectus filed under Rule 424 under the Securities Act, in conformity with the requirements of the Securities Act, and such other documents as such
Selling Holders and underwriters, if any, may reasonably request in order to facilitate the public sale or other disposition of the Registrable Securities owned by such Selling Holders; 

  
 34 

	(v)	 use reasonable efforts to cause such Registrable Securities to be listed on each securities exchange on which
similar securities issued by the Company are then listed; 

  

	(vi)	 use reasonable efforts to provide and cause to be maintained a transfer agent and registrar for all Registrable
Securities covered by such Registration Statement from and after a date not later than the effective date of such Registration Statement; 

  

	(vii)	 as promptly as practicable notify in writing the holders of Registrable Securities and the underwriters, if
any, of the following events: (A) the filing of the Registration Statement, any amendment thereto, the prospectus or any prospectus supplement related thereto or post-effective amendment to such Registration Statement utilized in connection
therewith, and, with respect to such Registration Statement or any post-effective amendment thereto, when the same has become effective; (B) any request by the SEC or any other U.S. or state governmental authority for amendments or supplements
to such Registration Statement or the prospectus or for additional information; (C) the issuance by the SEC of any stop order suspending the effectiveness of such Registration Statement or the initiation of any proceedings by any person for
that purpose; (D) the receipt by the Company of any notification with respect to the suspension of the qualification of any Registrable Securities for sale under the securities or “blue sky” laws of any jurisdiction or the initiation
or threat of any proceeding for such purpose; (E) if at any time the representations and warranties of the Company contained in any agreement (including any underwriting agreement) related to such registration cease to be true and correct in
any material respect; and (F) upon the happening of any event that makes any statement made in such Registration Statement or related prospectus or any document incorporated or deemed to be incorporated therein by reference untrue in any
material respect or that requires the making of any changes in such registration statement, prospectus or documents so that, in the case of such Registration Statement, it will not contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary to make the statements therein not misleading, and that in the case of the prospectus, it will not contain any untrue statement of a material fact or omit to state any material fact necessary
in order to make the statements therein, in light of the circumstances under which they were made, not misleading; provided, in the case of clause (F), that such notice need not include the nature or details concerning such events;

  

	(viii)	 use reasonable efforts to obtain the withdrawal of any order suspending the effectiveness of such Registration
Statement, or the lifting of any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities for sale in any jurisdiction at the earliest reasonable practicable date, except that the Company shall not for
any such purpose be required to (A) qualify generally to do business as a foreign corporation or as a dealer in securities in any jurisdiction wherein it would not but for the requirements of this clause (viii) be obligated to be so
qualified, (B) subject itself to taxation in any such jurisdiction or (C) file a general consent to service of process in any such jurisdiction; 

  
 35 

	(ix)	 cooperate with each seller of Registrable Securities and each underwriter or agent participating in the
disposition of such Registrable Securities and their respective counsel in connection with any filings required to be made with the Financial Industry Regulatory Authority, Inc.; and 

 

	(x)	 prior to any public offering of Registrable Securities, use reasonable efforts to register or qualify or
cooperate with the Selling Holders in connection with the registration or qualification (or exemption from such registration or qualification) of such Registrable Securities for offer and sale under the applicable state securities or “blue
sky” laws of those jurisdictions within the United States as any holder reasonably requests in writing to keep each such registration or qualification (or exemption therefrom) effective until the Registration Termination Date; provided, that
the Company will not be required to (A) qualify generally to do business as a foreign corporation or as a dealer in securities in any jurisdiction wherein it would not but for the requirements of this clause (xi) be obligated to be so
qualified, (B) subject itself to taxation in any such jurisdiction or (C) file a general consent to service of process in any such jurisdiction; 

  

	(xi)	 use reasonable efforts to cooperate with the holders to facilitate the timely preparation and delivery of
certificates or book-entry securities representing Registrable Securities to be delivered to a transferee pursuant to the Registration Statements, which certificates or book-entry securities shall be free, to the extent permitted by the Indenture
and applicable law, of all restrictive legends, and to enable such Registrable Securities to be in such denominations and registered in such names as any such holders may request in writing; and in connection therewith, if required by the
Company’s transfer agent, the Company will promptly after the effectiveness of the Registration Statement cause to be delivered to its transfer agent when and as required by such transfer agent from time to time, any authorizations,
certificates, directions and other evidence required by the transfer agent which authorize and direct the transfer agent to issue such Registrable Securities without legend upon sale by the holder of such shares of Registrable Securities under the
Registration Statement; and 

  

	(xii)	 agrees with each holder of Registrable Securities that, in connection with any Underwritten Offering or other
resale pursuant to the Registration Statement in accordance with the terms hereof, it will use reasonable efforts to negotiate in good faith and execute all customary indemnities, underwriting agreements and other documents reasonably required under
the terms of such underwriting arrangements (in each case on terms reasonably acceptable to the Company), including using reasonable efforts to procure customary legal opinions and auditor “comfort” letters. 

 

	(b)	 The Company may require each Selling Holder and each underwriter, if any, to (i) furnish the Company in
writing such information regarding each Selling Holder or underwriter and the distribution of such Registrable Securities as the Company may from time to time reasonably request in writing to complete or amend the information required by such
Registration Statement and/or any other documents relating to such registered offering, and (ii) execute and deliver, or cause the execution or delivery of, and to perform under, or cause the performance under, any agreements and instruments
reasonably requested by the Company to effectuate such registered offering, including, without limitation, opinions of counsel and questionnaires. If the Company requests that the holders of Registrable Securities take any of the actions referred to
in this Section 5.03(b), such holders shall take such action promptly and as soon as reasonably practicable following the date of such request. 

  
 36 

	(c)	 Each Selling Holder agrees that upon receipt of any notice from the Company of the happening of any event of
the kind described in clauses (B), (C), (D), (E) and (F) of Section 5.03(a)(vii), such Selling Holder shall forthwith discontinue such Selling Holder’s disposition of Registrable Securities pursuant to the applicable Registration
Statement and prospectus relating thereto until such Selling Holder is advised in writing by the Company that the use of the applicable prospectus may be resumed, and has received copies of any additional or supplemental filings that are
incorporated or deemed to be incorporated by reference in such prospectus. The Company shall use reasonable efforts to cure the events described in clauses (B), (C), (D), (E) and (F) of Section 5.03(a)(vii) so that the use of the
applicable prospectus may be resumed at the earliest reasonably practicable moment. 

 Section 5.04. Expenses. The Company
shall pay all Registration Expenses in connection with a registration pursuant to this Article 5 and any Rule 144A offering pursuant to Section 5.02(d); provided that each holder of Registrable Securities participating in an offering
shall pay any applicable underwriting fees, discounts, selling commissions, agency fees, brokers’ commissions and transfer taxes, if any, on the Registrable Securities sold by such holder and similar charges. 

Section 5.05. Registration Indemnification. 
  

	(a)	 The Company agrees, without limitation as to time, to indemnify and hold harmless, to the fullest extent
permitted by law, each Selling Holder and its Affiliates and their respective officers, directors, members, shareholders, employees, managers, partners, accountants, attorneys, advisors and agents and each Person who controls (within the meaning of
Section 15 of the Securities Act and Section 20 of the Exchange Act) such Selling Holder or such other indemnified Person and the officers, directors, members, shareholders, employees, managers, partners, accountants, attorneys, advisors
and agents of each such controlling Person, each underwriter, if any, and each Person who controls (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act) such underwriter (collectively, the
“Indemnified Persons”), from and against all losses, claims, damages, liabilities, costs, expenses (including reasonable expenses of investigation and reasonable attorneys’ fees and expenses), judgments, fines, penalties,
charges and amounts paid in settlement (collectively, the “Losses”), as incurred, arising out of, caused by, resulting from or relating to any untrue statement (or alleged untrue statement) of a material fact contained in any
Registration Statement, prospectus or preliminary prospectus, in each case related to such Registration Statement, or any amendment or supplement thereto or any omission (or alleged omission) of a material fact required to be stated therein or
necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading and (without limitation of the preceding portions of this Section 5.05(a)) will reimburse each such Selling Holder, each of
its Affiliates, and each of their respective officers, directors, members, shareholders, employees, managers, partners, accountants, attorneys, advisors and agents and each such Person who controls each such Selling Holder and the officers,
directors, members, shareholders, employees, managers, partners, accountants, attorneys, advisors and agents of each such controlling Person, each such underwriter and each such Person who controls any such underwriter, for any legal and any other
expenses reasonably incurred in connection with investigating and defending or settling any such claim, Loss, damage, liability or action, except insofar as the same are caused by any information regarding a holder of Registrable Securities or
underwriter furnished in writing to the Company by any such person or any Selling Holder or underwriter expressly for use therein. 

  
 37 

	(b)	 In connection with any Registration Statement in which a Selling Holder is participating, without limitation as
to time, each such Selling Holder shall, severally and not jointly, indemnify the Company, its directors and officers, and each Person who controls (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act)
the Company, from and against all Losses, as incurred, arising out of, caused by, resulting from or relating to any untrue statement (or alleged untrue statement) of material fact contained in the Registration Statement, prospectus or preliminary
prospectus or any amendment or supplement thereto or any omission (or alleged omission) of a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not
misleading, and (without limitation of the preceding portions of this Section 5.05(b)) will reimburse the Company, its directors and officers and each Person who controls the Company (within the meaning of Section 15 of the Securities Act
and Section 20 of the Exchange Act) for any legal and any other expenses reasonably incurred in connection with investigating and defending or settling any such claim, Loss, damage, liability or action, in each case solely to the extent, but
only to the extent, that such untrue statement or omission is made in such registration statement, prospectus or preliminary prospectus or any amendment or supplement thereto in reliance upon and in conformity with written information regarding the
Selling Holder furnished to the Company by such Selling Holder for inclusion in such registration statement, prospectus or preliminary prospectus or any amendment or supplement thereto. 

 

	(c)	 Any Person entitled to indemnification hereunder shall give prompt written notice to the indemnifying party of
any claim with respect to which it seeks indemnification; provided, however, the failure to give such notice shall not release the indemnifying party from its obligation, except to the extent that the indemnifying party has been actually and
materially prejudiced by such failure to provide such notice on a timely basis. 

  

	(d)	 In any case in which any such action is brought against any indemnified party, the indemnified party shall
promptly notify in writing the indemnifying party of the commencement thereof, and the indemnifying party will be entitled to participate therein, and, to the extent that it may wish, to assume the defense thereof, with counsel reasonably
satisfactory to such indemnified party, and after notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof and acknowledging the obligations of the indemnifying party with respect to such
proceeding, the indemnifying party will not (so long as it shall continue to have the right to defend, contest, litigate and settle the matter in question in accordance with this paragraph) be liable to such indemnified party hereunder for any legal
or other expense subsequently incurred by such indemnified party in connection with the defense thereof other than reasonable costs of investigation, supervision and monitoring (unless (i) such indemnified party reasonably objects to such
assumption on the grounds that there may be defenses available to it which are different from or in addition to the defenses available to such indemnifying party and, as a result, a conflict of interest exists or (ii) the indemnifying party
shall have failed within a reasonable period of time to assume such defense and the indemnified party is or would reasonably be expected to be materially prejudiced by such delay, in either event the indemnified party shall be promptly reimbursed by
the indemnifying party for the expenses incurred in connection with retaining one separate legal counsel (for the avoidance of doubt, for all 

  
 38 

	 	
indemnified parties in connection therewith)). For the avoidance of doubt, notwithstanding any such assumption by an indemnifying party, the indemnified party shall have the right to employ
separate counsel in any such matter and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such indemnified party except as provided in the previous sentence. An indemnifying party shall not be
liable for any settlement of an action or claim effected without its consent (which consent shall not be unreasonably withheld, conditioned or delayed). No matter shall be settled by an indemnifying party without the consent of the indemnified party
(which consent shall not be unreasonably withheld, conditioned or delayed), unless such settlement (x) includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such claim or
proceeding, (y) does not include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of any indemnified party and (z) is settled solely for cash for which the indemnified party would be entitled
to indemnification hereunder. The failure of an indemnified party to give notice to an indemnifying party of any action brought against such indemnified party shall not relieve the indemnifying party of its obligations or liabilities pursuant to
this Agreement, except to the extent such failure adversely prejudices the indemnifying party. 

  

	(e)	 The indemnification provided for under this Agreement shall survive the sale or other transfer of the
Registrable Securities and the termination of this Agreement. 

  

	(f)	 If recovery is not available under the foregoing indemnification provisions for any reason or reasons other
than as specified therein, any Person who would otherwise be entitled to indemnification by the terms thereof shall nevertheless be entitled to contribution with respect to any Losses with respect to which such Person would be entitled to such
indemnification but for such reason or reasons, in such proportion as is appropriate to reflect the relative fault of the indemnifying party, on the one hand, and such indemnified party, on the other hand, in connection with the actions, statements
or omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue
or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party, the Persons’ relative knowledge and access to information concerning
the matter with respect to which the claim was asserted, the opportunity to correct and prevent any statement or omission, and other equitable considerations appropriate under the circumstances. It is hereby agreed that it would not necessarily be
equitable if the amount of such contribution were determined by pro rata or per capita allocation that does not take into account the equitable considerations referred to in the immediately preceding sentence. Notwithstanding any other provision of
this Agreement, no holder of Registrable Securities shall be required to contribute, in the aggregate, any amount in excess of its net proceeds from the sale of the Registrable Securities subject to any actions or proceedings over the amount of any
damages, indemnity or contribution that such holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No Person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not found guilty of such fraudulent misrepresentation. 

  
 39 

	(g)	 The indemnification and contribution agreements contained in this Section 5.05 are in addition to any
liability that the indemnifying party may have to the indemnified party and do not limit other provisions of this Agreement that provide for indemnification. 

Section 5.06. Facilitation of Sales Pursuant to Rule 144. For as long as any Purchaser or its Affiliates Beneficially Owns Notes or any Company
Common Stock issued or issuable upon conversion thereof, to the extent it shall be required to do so under the Exchange Act, the Company shall use reasonable efforts to timely file the reports required to be filed by it under the Exchange Act or the
Securities Act (including the reports under Sections 13 and 15(d) of the Exchange Act referred to in subparagraphs (c)(1) and (i)(2) of Rule 144) and submit all required Interactive Data Files (as defined in Rule 11 of Regulation S-T of the SEC), and shall use reasonable efforts to take such further necessary action as any holder of Subject Securities may reasonably request in connection with the removal of any restrictive legend on the
Subject Securities being sold, all to the extent required from time to time to enable such holder to sell the Subject Securities without registration under the Securities Act within the limitations of the exemption provided by Rule 144 (including
those referred to in subparagraph (i) of Rule 144). 
 ARTICLE 6 

MISCELLANEOUS 
 Section 6.01.
Survival of Representations and Warranties. All covenants and agreements contained herein, other than those which by their terms apply in whole or in part at or after the Closing (which shall survive the Closing), shall terminate as of the
Closing, provided nothing herein shall relieve any party of liability for any breach of such covenant or agreement before it terminated. The representations and warranties made herein shall survive for six (6) months following the Closing Date
and shall then expire; provided that nothing herein shall relieve any party of liability for any inaccuracy or breach of such representation or warranty to the extent that any good faith allegation of such inaccuracy or breach is made in
writing prior to such expiration. 
 Section 6.02. Notices. All notices and other communications hereunder shall be in writing and shall be
deemed to have been duly given if delivered personally, sent by overnight courier or sent via email (with receipt confirmed) as follows: 
  

	(a)	 If to any Purchaser, to the notice information set forth on the signature page hereto: 

with a copy (which shall not constitute actual or constructive notice) to: 

Milbank LLP 
 55 Hudson Yards 

New York, NY 10001 
 Attention:
Eric R. Reimer; Casey T. Fleck 
 Email: ereimer@milbank.com; cfleck@milbank.com 

 

	(b)	 If to the Company, to: 

Nikola Corporation 

  
 40 

 4141 E Broadway Road 

Phoenix, AZ 85040 
 Attn: Chief
Legal Officer 
 Email: 
 with a
copy (which will not constitute actual or constructive notice) to: 
 Pillsbury Winthrop Shaw Pittman LLP 

2550 Hanover Street 
 Palo Alto,
CA 94304 
 Attention: Stanley E. Pierson; Gabriella A. Lombardi; Julie Park 

Email: stan.pierson@pillsburylaw.com; gabriella.lombardi@pillsburylaw.com; 

            julie.park@pillsburylaw.com 

or to such other address or addresses as shall be designated in writing. All notices shall be deemed effective (a) when delivered
personally (with written confirmation of receipt, by other than automatic means, whether electronic or otherwise), (b) when sent by email if received before 5:00 pm Eastern Time; or (c) one (1) Business Day following the day sent by overnight
courier. 
 Section 6.03. Entire Agreement; Third Party Beneficiaries; Amendment. 

 

	(a)	 This Agreement and the other Transaction Agreements set forth the entire agreement between the parties hereto
with respect to the Transactions, supersede all prior agreements and understandings, both oral and written, among the parties and their respective Affiliates with respect to the subject matter hereof and thereof. 

 

	(b)	 This Agreement is not intended to and shall not confer upon any person other than the parties hereto, their
successors and permitted assigns any rights or remedies hereunder, provided that (i) Section 4.10 and Section 5.05 shall be for the benefit of and fully enforceable by each of the Indemnified Persons; and
(ii) Section 6.12 shall be for the benefit of and fully enforceable by each of the Specified Persons. 

  

	(c)	 Any provision of this Agreement may be amended or modified in whole or in part at any time by an agreement in
writing between the parties hereto executed in the same manner as this Agreement. No failure on the part of any party to exercise, and no delay in exercising, any right shall operate as a waiver thereof nor shall any single or partial exercise by
any party of any right preclude any other or future exercise thereof or the exercise of any other right. 

 Section 6.04.
Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed to constitute any original, but all of which together shall constitute one and the same document. Signatures to this Agreement transmitted
by facsimile transmission, by electronic mail in “portable document format” (“.pdf”) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document will have the same
effect as physical delivery of the paper document bearing the original signature. The words “execution,” “signed,” “signature,” “delivery,” and words of like import in or relating to this Agreement or any
document to be signed in connection with this 

  
 41 

 
Agreement shall be deemed to include electronic signatures, deliveries or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as
a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be, and the parties hereto consent to conduct the transactions contemplated hereunder by electronic means. 

Section 6.05. Public Announcements. The initial press release related to this Agreement and the Transactions shall be a press release to be
mutually agreed upon by the Company and Purchasers. Thereafter, either party may issue or make one or more press releases or public announcements related to this Agreement or the Transactions (in which case the other party shall (to the extent
permitted by applicable law) have the right to review and reasonably comment on such press release or announcement prior to issuance, distribution or publication); provided that the foregoing shall not apply to any press release or other
public announcement to the extent that it contains substantially the same factual information related to this Agreement and the Transactions as previously communicated publicly by one or more of the parties in accordance with this Section 6.05.
Without limiting the foregoing, the Company may file this Agreement with the SEC and may provide information about the subject matter of this Agreement in connection with equity or debt issuances, share repurchases, or marketing, informational or
reporting activities. The Company shall use its commercially reasonable efforts to file with the SEC a current report on Form 8-K (the “Disclosure Document”) as soon as possible after the
execution of this Agreement, which in any event shall be no later than by 8:30 a.m., New York City time, on the date of this Agreement (or, if such date is not a Business Day, on the first Business Day following the date of this Agreement),
disclosing all material terms of the transactions contemplated hereby and any other material, nonpublic information regarding the Company that the Company provided to the Purchasers on or prior to the date hereof. Upon the filing of the Disclosure
Document, to the Company’s knowledge, no Purchaser shall be in possession of any material, nonpublic information regarding the Company received from the Company or any of its officers, directors, or employees or agents, and the Purchasers shall
no longer be subject to any confidentiality or similar obligations under any current agreement, whether written or oral, with the Company or any of their respective affiliates in connection with the transactions contemplated hereby. 

Section 6.06. Expenses. The Company shall reimburse the Purchasers for the documented fees and expenses of Milbank LLP in connection with this
Agreement and the Transactions, in an aggregate amount not in excess of $150,000, which the Company shall do promptly and in any event within three (3) Business Days of the Closing Date. 

Section 6.07. Successors and Assigns. Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be
binding upon, the Company’s successors and assigns and each Purchaser’s successors and assigns, and no other person; provided, that neither the Company nor any Purchaser may assign its respective rights or delegate its respective
obligations under this Agreement without the written consent of the Company or such Purchaser, as applicable, whether by operation of law or otherwise, and any assignment by the Company or such Purchaser in contravention hereof shall be null and
void; provided further that (i) any Purchaser may assign all of its rights and obligations under this Agreement or, in the case of this Agreement, any portion thereof, to one or more Affiliates who execute and deliver to the
Company a Joinder and a duly completed and executed IRS Form W-8 or W-9, as applicable, 

  
 42 

 
and any such assignee who executes and delivers to the Company a Joinder shall be deemed a Purchaser hereunder and have all the rights and obligations of such Purchaser so assigned;
provided that no such assignment will relieve such assigning Purchaser of its obligations hereunder until the Closing; (ii) if the Company consolidates or merges with or into any Person and the Company Common Stock is, in whole or in
part, converted into or exchanged for securities of a different issuer in a transaction that does not constitute a Change in Control, then as a condition to such transaction the Company will cause such issuer to assume all of the Company’s
rights and obligations under this Agreement in a written instrument delivered to such Purchaser; and (iii) any Purchaser may assign all of its rights and obligations under this Agreement to a Permitted Counterparty. 

Section 6.08. Governing Law; Jurisdiction; Waiver of Jury Trial. 
  

	(a)	 This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without
giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of New York. In addition, each of the
parties hereto irrevocably agrees that any legal action or proceeding with respect to this Agreement and the rights and obligations arising hereunder, or for recognition and enforcement of any judgment in respect of this Agreement and the rights and
obligations arising hereunder brought by the other party hereto or its successors or assigns, may be brought and determined in the United States District Court for the Southern District of New York or any New York State court sitting in New York
City and hereby irrevocably consents and submits to the non-exclusive jurisdiction of each such court in personam, generally and unconditionally with respect to any action, suit or proceeding for itself
in respect of its properties, assets and revenues. Each of the parties hereto hereby irrevocably waives, and agrees not to assert as a defense, counterclaim or otherwise, in any action or proceeding with respect to this Agreement, (i) any claim
that it is not personally subject to the jurisdiction of the above named courts for any reason other than the failure to serve in accordance with this Section 6.08(a), (ii) any claim that it or its property is exempt or immune from the
jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (iii) to the
fullest extent permitted by the applicable law, any claim that (A) the suit, action or proceeding in such court is brought in an inconvenient forum, (B) the venue of such suit, action or proceeding is improper or (C) this Agreement,
or the subject matter hereof, may not be enforced in or by such courts. Each of the parties hereby agrees that service of any process, summons, notice or document by U.S. registered mail to the respective addresses set forth in Section 6.02
shall be effective service of process for any suit or proceeding in connection with this Agreement or the transactions contemplated hereby. 

  

	(b)	 EACH OF THE PARTIES TO THIS AGREEMENT HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO A TRIAL BY JURY IN ANY
ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY MAKES THIS WAIVER VOLUNTARILY AND SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS,
THE MUTUAL WAIVERS CONTAINED IN THIS SECTION 6.08. 

  
 43 

 Section 6.09. Severability. If any provision of this Agreement is determined to be invalid,
illegal or unenforceable, the remaining provisions of this Agreement shall remain in full force and effect provided that the economic and legal substance of, any of the Transactions is not affected in any manner materially adverse to any party. In
the event of any such determination, the parties agree to negotiate in good faith to modify this Agreement to fulfill as closely as possible the original intent and purpose hereof. To the extent permitted by law, the parties hereby to the same
extent waive any provision of law that renders any provision hereof prohibited or unenforceable in any respect. 
 Section 6.10. Specific
Performance. The parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. Accordingly, each party agrees
that in the event of any breach or threatened breach by any other party of any covenant or obligation contained in this Agreement, the non-breaching party shall be entitled (in addition to any other remedy
that may be available to it, whether in law or equity) to obtain (i) a decree or order of specific performance to enforce the observance and performance of such covenant or obligation, and (ii) an injunction restraining such breach or
threatened breach. Each of the parties agrees that it will not oppose the granting of an injunction, specific performance and other equitable relief on the basis that any other party has an adequate remedy at law or that any award of specific
performance is not an appropriate remedy for any reason at law or in equity. Any party seeking an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement shall not be
required to provide any bond or other security in connection with any such order or injunction. 
 Section 6.11. Headings. The headings of
Articles and Sections contained in this Agreement are for reference purposes only and are not part of this Agreement. 
 Section 6.12. Non-Recourse. This Agreement may only be enforced against, and any claim or cause of action based upon, arising out of, or related to this Agreement or the transactions contemplated hereby may only be brought
against the entities that are expressly named as parties hereto and their respective successors and assigns (including any Person that executes and delivers a Joinder). Except as set forth in the immediately preceding sentence, no past, present or
future director, officer, employee, incorporator, member, partners, stockholder, Affiliate, agent, attorney, advisor or representative of any party hereto or any of such party’s Affiliates (collectively, the “Specified
Persons”) shall have any liability for any obligations or liabilities of any party hereto under this Agreement or for any claim based on, in respect of, or by reason of, the transactions contemplated hereby. All obligations of any Purchaser
hereunder shall be several obligations of such Purchaser and, for the avoidance of doubt, not joint or joint and several obligations. 

[Remainder of page intentionally left blank.] 

  
 44 

 IN WITNESS WHEREOF, this Agreement has been executed by the parties hereto or by their
respective duly authorized officers, all as of the date first above written. 
  

			
	NIKOLA CORPORATION
		
	By:	 	 /s/ Kim Brady

		 	Name: Kim Brady
		 	Title: Chief Financial Officer
	
	NIKOLA SUBSIDIARY CORPORATION
		
	By:	 	 /s/ Kim Brady

		 	Name: Kim Brady
		 	Title: Chief Financial Officer

 [Signature Page to Investment Agreement] 

 IN WITNESS WHEREOF, this Agreement has been executed by the parties hereto or by their
respective duly authorized officers, all as of the date first above written. 
  

			
	ANTARA CAPITAL LP, on behalf of certain advised or managed funds and accounts
		
	By:	 	 /s/ Himanshu Gulati

		 	Name: Himanshu Gulati
		 	Title: CIO / Founder
	
	Notice Information:
	
	Address:
		
		 	55 Hudson Yards Suite 47C
		 	New York, NY 10001
	
	Email:

 [Signature Page to Investment Agreement] 

 SCHEDULE 1 

PURCHASERS 
  

					
	 Purchaser
	  	Principal Amount of Notes to be
Purchased	 
	 Antara Capital LP, on behalf of certain advised or managed funds and accounts
	  	$	 200,000,000	 
		  	  
	  
	 
	 Total
	  	$	 200,000,000	 

 SCHEDULE 2 

GUARANTORS 
 Nikola Subsidiary Corporation

  
 1 

 EXHIBIT A 

FORM OF INDENTURE 

  
 2 

 EXHIBIT B 

FORM OF JOINDER 

___________, 20__ 
 The undersigned is executing
and delivering this Joinder pursuant to that certain Investment Agreement dated as of April 30, 2022 (as amended, restated, supplemented or otherwise modified in accordance with the terms thereof, the “Investment Agreement”) by
and among Nikola Corporation, Nikola Subsidiary Corporation and the other parties listed therein and any other Persons who become a party thereto in accordance with the terms thereof. Capitalized terms used but not defined in this Joinder shall have
the respective meanings ascribed to such terms in the Investment Agreement. 
 By executing and delivering this Joinder to the Investment Agreement, the
undersigned hereby adopts and approves the Investment Agreement and agrees, effective commencing on the date hereof, to become a party to, and to be bound by and comply with the provisions of, the Investment Agreement applicable to the Purchaser in
the same manner as if the undersigned were the original Purchaser signatory to the Investment Agreement. 
 The undersigned acknowledges and agrees that
Sections 6.02, 6.03, 6.07, 6.08 and 6.12 of the Investment Agreement are incorporated herein by reference, mutatis mutandis. 

[Signature pages follow] 

 Accordingly, the undersigned has executed and delivered this Joinder as of the first date written above.

  

			
	  

	By:	 	  

		 	Name:
		 	Title:
	Address:
	Email:

 [Signature Page to Joinder]Exhibit
10.1

 

PROVENTION
BIO, INC.

SCIENTIFIC
ADVISOR AGREEMENT

 

THIS
SCIENTIFIC ADVISOR AGREEMENT (this “Agreement”) is made effective as of June 1, 2022 (the “Effective Date”),
by and between by and between PROVENTION BIO, INC., a Delaware corporation (the “Company”), and Dr. Jeffrey Bluestone,
PhD (the “Advisor”; together with the Company, collectively the “Parties”, and individually, a
“Party”).

 

RECITALS

 

WHEREAS,
the Advisor has acquired special education, training and experience which qualifies the Advisor to provide the Services (as defined below)
to the Company; and

 

WHEREAS,
the Company desires to engage the Advisor and the Advisor desires to be engaged by the Company, upon the terms and conditions of this
Agreement.

 

NOW,
THEREFORE, in consideration of the foregoing, the mutual promises hereinafter set forth, and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Parties intending to be legally bound hereto hereby agree as follows:

 

1.
Engagement. The Company hereby agrees to retain the Advisor to provide the Services (as defined below) and the Advisor
hereby accepts that engagement and agrees to provide the Services to the Company upon the terms and conditions hereinafter set forth.

 

2.
Term. Subject to the provisions of Section 8 below, the Advisor’s engagement with the Company shall commence
on the Effective Date and continue until the earlier of (a) the business day immediately prior to the Company’s 2023 annual meeting
of stockholders and (b) May 17, 2023 (the “Term”, and the last day of the Term, the “Termination Date”).

 

3.
Position, Duties, Responsibilities.

 

3.1
Duties. During the Term, the Advisor shall serve as a scientific advisor to the Company and shall, in such capacity, perform such
scientific advisory services (“Services”) as reasonably requested by the Company’s Chief Executive Officer or
the Chairman of the Board of Directors (the “Board”) of the Company. The Advisor shall devote the Advisor’s
commercially reasonable efforts and attention to the performance of the Services for the Company on a timely basis for up to 12 hours
during the Term.

 

3.2
Independent Contractor. It is understood and agreed by the Parties that the Advisor is an independent contractor in the performance
of the Services under this Agreement and that Advisor shall perform the Services under the control of the Company as to the result of
such Services only and not as to the means by which such result is accomplished. This Agreement does not create an employer-employee
relationship between the Advisor and the Company and the Advisor shall have no right to receive any employee benefits including, but
not limited to, health and accident insurance, life insurance, sick leave and/or vacation. The Advisor agrees to pay all taxes including,
self-employment taxes due in respect of any compensation provided to the Adviser hereunder and shall indemnify the Company in the event
the Company is required to pay any such taxes on behalf of the Advisor.

 

    	 

     

    

 

4.
Consideration, Benefits, Expenses.

 

4.1
Consideration; Post-Termination Exercise Period. As full compensation for the Services to be provided by the Advisor under this
Agreement, the option to purchase 33,000 shares of common stock of the Company (the “Stock Option”) granted under
the Company’s 2017 Equity Incentive Plan (the “Plan”) to the Advisor on May 17, 2022, shall continue to vest
in accordance with its terms so long as the Advisor is providing the Services and shall vest in full on the Termination Date. The Company
acknowledges and agrees that the provision of Services hereunder by the Advisor shall constitute “Continuous Service” for
purposes of the Plan, which will result in outstanding options to purchase common stock of the Company, including the Stock Option, continuing
to vest for so long as the Advisor provides the Services. The post-termination period for exercising the Stock Option and any other options
to purchase common stock of the Company held by the Advisor shall commence on the Termination Date and shall terminate in accordance
with the terms of such options.

 

4.2
Reimbursement of Expenses. The Company shall promptly reimburse the Advisor for any reasonable costs and out of pocket expenses
incurred by the Advisor in connection with the Services specifically requested by Company and actually performed by the Advisor pursuant
to the terms of this Agreement.

 

5.
Confidentiality.

 

5.1
“Confidential Information” shall mean for the purposes of this Agreement all of the trade secrets, know-how, ideas,
business plans, pricing information, the identity of and any information concerning customers or suppliers, computer programs (whether
in source code or object code), procedures, processes, strategies, methods, systems, designs, discoveries, inventions, production methods
and sources, marketing and sales information, information received from others that the Company is obligated to treat as confidential
or proprietary, information relating to the Company’ s corporate finance and liquidity transactions, the Company’s internal
documents, such as its and its affiliates’ operating agreements, and by-laws, contracts with employees or third parties and any
other technical, operating, financial and other business information relating to the Company, its business, potential business, operations
or finances, or the business of the Company’s affiliates or customers.

 

5.2
“Confidential Information” of the Company shall not be deemed to include information which Advisor can demonstrate by competent
evidence: (a) was in the public domain when disclosed by the Company to Advisor or subsequently becomes public through no act or failure
to act on the part of Advisor in breach of this Agreement or any fiduciary duty to the Company; or (b) was or is furnished to Advisor
by a third party not bound by any confidentiality obligation or other restriction on disclosure with respect to such information.

 

5.3
The Advisor shall only use Confidential Information for the benefit of the Company in the rendering of Services for the Company and will
not otherwise use or disclose such information to others, at any time, now or in future, directly or indirectly, (a) without prior express,
written permission in each instance of disclosure of an officer of the Company authorized to grant such permission or (b) except as permitted
under Section 5.4 of this Agreement. Subject to Section 5.4 of this Agreement, the Company may grant or deny permission to disclose in
each instance in its sole discretion. Subject to Section 5. below, upon termination of this Agreement, the Advisor shall destroy
or, upon the Company’s request, immediately return to the Company, all drawings, blueprints, manuals, specification documents,
documentation, source or object codes, tape discs and any other storage media, letters, notes, notebooks, reports, flowcharts, and all
other materials in his possession or under his control relating to the Confidential Information and/or the Services, as well as all other
property belonging to the Company which is then in the Advisor’s possession or under his control.

 

5.4
Notwithstanding any other provision of this Agreement, disclosure of Confidential Information of the Company shall not be precluded if
such disclosure is required under applicable law, regulation, or valid order of a court or other governmental body to which Advisor is
subject, provided that, Advisor shall, to the extent practicable, first have given written notice to the Company of the need for such
disclosure reasonably in advance so that the Company may (if it elects) seek a protective order or other confidential treatment of its
Confidential Information.

 

    	2

     

    

 

5.5
The Advisor agrees that in rendering Services to the Company, the Advisor will disclose to the Company only information that the Advisor
has the right to freely disclose without incurring legal liability to, or violating rights of, others.

 

5.6
The Advisor understands that the Advisor will not be held criminally or civilly liable under any federal or state trade secret law for
the disclosure of a trade secret that (a) is made (i) in confidence to a federal, state, or local government official, either directly
or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b)
is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; provided that
notwithstanding this immunity from liability, the Advisor may be held liable if the Advisor unlawfully accesses trade secrets by
unauthorized means. In addition, the Advisor understands that nothing contained in this Agreement limits the Advisor’s ability
to communicate with any federal, state, or local governmental agency or entity concerning matters relevant to the governmental agency
or entity.

 

5.7
Nothing in this Section 5 is intended to limit any remedy of the Company under applicable law.

 

6.
Materials and Developments.

 

6.1
Materials. All documentation, information, and biological, chemical and other documents or materials furnished to the Advisor
by or on behalf of the Company (“Materials”) and all associated intellectual property rights therein will remain the
exclusive property of the Company. The Advisor will use Materials provided by the Company only as necessary to perform the Services and
will treat them in accordance with the requirements of this Section 6.1. The Advisor will not use or evaluate those Materials
or any portions thereof for any other purpose except as directed or permitted in writing by the Company. Without the Company’s
prior express written consent, the Advisor will not analyze the Materials, or transfer or make the Materials available to third parties.

 

6.2
Deliverables. The Advisor will promptly and fully disclose all Deliverables (as defined below) to the Company. The Advisor hereby
assigns and agrees to assign to the Company (or as otherwise directed by the Company) all rights in the United States and throughout
the world to inventions, discoveries, improvements, ideas, designs, processes, formulations, products, computer programs, works of authorship,
databases, mask works, trade secrets, know-how, information, data, documentation, reports, research, creations and other products arising
from or made in the performance of the Services (whether or not patentable or subject to copyright or trade secret protection) (collectively,
“Deliverables”). The Company will have the right to use Deliverables for any and all purposes. During and after the
Term, the Advisor will cooperate fully in obtaining patent and other proprietary protection for any patentable Deliverables, all in the
name of the Company and at the Company’s cost and expense. Such cooperation will include, without limitation, executing and delivering
all requested applications, assignments and other documents, and taking such other measures as the Company may reasonably request in
order to secure, prosecute, perfect and enforce the Company’s rights in the Deliverables. The Advisor will not charge the Company
for time spent in complying with these obligations. The Advisor appoints the Company its attorney-in-fact to execute and deliver any
such documents on behalf of the Advisor if the Advisor fails to do so. The Advisor will, however, retain full ownership rights in and
to all templates, programs and other materials developed or obtained or licensed from third parties by the Advisor (“Advisor
Property”) prior to or independent of the Services, regardless of whether such Advisor Property is used in the performance
of the Services. The Advisor hereby grants to the Company a perpetual, non-exclusive, fully paid-up worldwide license to use Advisor
Property solely to the extent required for the Company’s use of the Deliverables. The Advisor also waives all claims to any moral
rights or other special rights that the Advisor may have or accrue in any Deliverable.

 

6.3
Work at Third Party Facilities. The Advisor will not use any third-party facilities or intellectual property in performing the
Services without the Company’s prior written consent.

 

    	3

     

    

 

7.
Termination; Survival.

 

7.1
Termination. Each Party may terminate this Agreement at any time without cause and without liability to any other Party upon not
less than thirty (30) days’ prior written notice to the other Party. If not earlier terminated, this Agreement shall automatically
terminate on the Termination Date.

 

7.2
Effect of Termination of Services. In the event of termination of this Agreement, howsoever occurring, neither the Advisor nor
his beneficiary or estate will have any further rights or claims against the Company, its affiliates, or its subsidiaries under this
Agreement except to receive reimbursement for any expenses for which the Advisor shall not have theretofore been reimbursed as provided
in Section 4.2 (the “Final Reimbursement”). The Final Reimbursement will be paid by the Company to the Advisor
within thirty (30) days following the date of termination. For the avoidance of doubt, upon termination of this Agreement prior to the
Termination Date, the Stock Option will automatically terminate. Upon a termination of this Agreement, the Advisor shall be entitled
to exercise any vested stock options in accordance with the terms of the Plan and the agreements evidencing such stock options.

 

8.
Representations, Warranties and Covenants. The Advisor represents and warrants that the Advisor has the right to enter
into this Agreement and that performing the Advisor’s obligations under this Agreement does not violate any law, rule of ethics,
contract, agreement or third party right. In performing the Services, the Advisor shall perform the Services in a professional manner
in accordance with applicable laws, rules, regulations and industry standards and shall comply, with all applicable business conduct,
regulatory and health and safety guidelines established by the Company or any governmental authority with respect to the Company’s
business.

 

9.
Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of New Jersey,
without regard to principles of conflicts of law. Any and all actions arising out of this Agreement or the Advisor’s engagement
by Company or termination therefrom shall be brought and heard in the state and federal courts of the State of New Jersey and the parties
hereto hereby irrevocably submit to the exclusive jurisdiction of any such courts. The Company
and THE ADVISOR HEREBY WAIVE THEIR RESPECTIVE RIGHT TO TRIAL BY JURY IN ANY ACTION CONCERNING THIS AGREEMENT OR ANY AND ALL MATTERS
ARISING DIRECTLY OR INDIRECTLY HEREFROM AND REPRESENT THAT THEY HAVE CONSULTED WITH COUNSEL OF THEIR CHOICE OR HAVE CHOSEN VOLUNTARILY
NOT TO DO SO SPECIFICALLY WITH RESPECT TO THIS WAIVER.

 

10.
Miscellaneous.

 

10.1
Assignment. The Company shall have the right to assign its rights and obligations under this Agreement to a party that assumes
the Company’s obligations hereunder. The Advisor shall not have the right to assign its rights or obligations under this Agreement
without the prior written consent of the Company.

 

10.2
Entire Agreement; Counterparts. This Agreement supersedes and replaces all previous agreements between the Parties to this Agreement
relating to the rendering of Services by the Advisor for the Company and constitutes the entire agreement and understanding between the
Parties relative to the rendering of Services by the Advisor for the Company. This Agreement will not be amended or modified nor may
any of its terms be waived except by a writing signed by both of the Parties. This Agreement may be executed in counterparts, each of
which will be deemed an original, but all those counterparts together will constitute one and the same instrument. For the avoidance
of doubt, nothing in this Agreement shall amend any indemnification agreement entered into by Advisor and the Company in respect of his
prior service on the Board.

 

10.3
Headings. Headings and subheadings are for convenience only and shall not be deemed to be a part of this Agreement.

 

10.4
Waiver. Any waiver by the Company of a breach of any provision of this Agreement shall not operate or be construed as a waiver
of any subsequent breach of the same or any other provision hereof. All waivers by the Company shall be in writing.

 

10.5
Severability. In case any one or more of the provisions or parts of a provision contained in this Agreement shall, for any reason,
be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any
other provision or part of a provision of this Agreement.

 

[Signature
page to follow]

 

    	4

     

    

 

IN
WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the date first written above.

 

	COMPANY:
    	 
	 	 	 
	PROVENTION
    BIO, INC.	 
	 	 	 
	By:	/s/
    Ashleigh Palmer	 
	 	 	 
	Title:	Chief
    Executive Officer	 
	 	 	 
	ADVISOR:
    JEFFREY BLUESTONE, PHD	 
	 	 	 
	By:	/s/
    Jeffrey Bluestone

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}]]